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ABSTRACT 
 The spectrum of human pathogens and the infectious diseases they cause is 
continuously changing through evolution and changes in the way human populations 
interact with the surrounding environment. It is known that modern agriculture -very 
large scale, industrialized and fungicide dependent - was one of the turning points in the 
history of infectious diseases. Over the last three decades, clinically important fungi 
have become more prevalent, mostly due to medical advances that allow the survival of 
an increasing number of debilitated and immunocompromised patients. Fungicides with 
similar chemical structure and mode of action to those used in medicine are also widely 
used in agriculture. Thus, a few years ago a critical problem emerged – the development 
of cross-resistance between agricultural and human antifungals in clinically relevant 
species of Aspergillus and Candida.  
The present study aims to provide insights whether the acquisition of resistance 
can arise from nature and impact on human health.  
It is known that the epidemiological landscape of fungal invasive infections (IFI) 
is changing. Therefore, a national multicentric surveillance study was carried out. From 
this study important clinical and demographic data were obtained as well as information 
regarding the in vitro susceptibility profile of yeast isolates. Candida albicans remains 
the most frequent agent of IFI but the prevalence of non-albicans keeps increasing. The 
overall susceptibility rates ranged from 84 to 98% to azoles and 74 to 97% to 
echinocandins.  
From this newly assembled collection, our next step was to determine its in vitro 
susceptibility to the most frequently used agricultural fungicides. Susceptible isolates of 
C. albicans, C. parapsilosis and C. glabrata to both clinical and agricultural antifungals 
were selected; an in vitro induction assay was started with one of the most frequently 
 xxviii 
 
used fungicide in Portugal – Prochloraz (PCZ), at sub-inhibitory concentrations. During 
the 90 days of induction, minimal inhibitory concentration (MIC) values were 
continuously evaluated and after 10 days of testing all Candida species revealed a 32 to 
64 times higher MIC value to the inducer fungicide. C. glabrata was the only species 
developing cross-resistance to clinical azoles after 60 days of exposure to the 
agricultural fungicide. After screening the most common azole resistance mechanisms, 
we found that PCZ selective pressure triggered an upregulation of the ATP Binding 
Cassette multidrug transporter genes and the transcription factor, PDR1. Single point 
mutation previously associated with azole resistance was described in PDR1 while in 
ERG11 gene several synonymous single nucleotide polymorphisms were found. These 
results provide possible explanations for the worldwide increasing prevalence of C. 
glabrata and the associated poor clinical outcome associated with infections by this 
species. 
The following work recreated a similar approach with another clinical relevant 
fungal pathogen – A. fumigatus. Two clinical and one environmental isolate were daily 
incubated with sub-inhibitory concentrations of PCZ. The fungicide exposure induced 
morphological changes and a significant increase of MIC value to PCZ, as well as 
cross-resistance to all the tested clinical azoles within the first 30 days of the assay. 
In the last study we aimed to review the national and global origin of azole 
antifungal resistance from nature to clinical settings. After such state of art revision we 
were forced to conclude that a fungicide-based plant protection agriculture remains 
essential to maintain the needed high crop production. In order to prevent or delay the 
development of cross-resistance some efforts should be made by the agriculture 
communities such as rotation of fungicides with different modes of action during the 
crop campaign and making more efficient fungicide mixtures of multi-site inhibitors, 
 xxix 
 
therefore excluding the use of monofungicides. Also, surveillance studies should be 
implemented in order to follow the variation in these fungal species distribution and 
resistance rate to both agricultural and clinical antifungals. 
 In summary, this dissertation highlights the occurrence of antifungal cross-
resistance between agriculture and medicine involving two relevant species of 
Aspergillus and Candida. Both pathogenic fungi showed that agricultural fungicides are 
capable of inducing cross-resistance to medical antifungals. 
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RESUMO 
A quantidade de agentes patogénicos e as doenças infeciosas que estes causam 
está continuamente a mudar e esta evolução ocorre devido às interações entre seres 
humanos e com o meio ambiente. A agricultura moderna, de larga escala, muito 
industrializada e altamente dependente de fungicidas, foi um dos pontos de viragem na 
história das doenças infeciosas. Ao longo das últimas três décadas, os fungos 
medicamente importantes tornaram-se mais prevalentes, sobretudo devido a técnicas 
médicas avançadas que permitem a sobrevivência de um número crescente de doentes 
muito debilitados e imunocomprometidos. Fungicidas, com estrutura química e modo 
de ação muito semelhantes aos antifúngicos médicos, são frequentemente usados na 
agricultura. Assim sendo, há alguns anos atrás surgiu um novo problema – o 
desenvolvimento de resistência cruzada entre antifúngicos agrícolas e clínicos em 
espécies clinicamente relevantes de Aspergillus e Candida.  
O presente estudo procurou esclarecer se a aquisição de resistência pode surgir 
da natureza e sobre o seu impacto na saúde humana. 
Dado que a epidemiologia destas infeções fúngicas invasivas (IFI) tem vindo a 
mudar, foi inicialmente realizado um estudo multicêntrico a nível nacional. Foram 
obtidos dados clínicos e demográficos e, resultados importantes sobre o perfil de 
suscetibilidade in vitro destes isolados clínicos. A levedura Candida albicans continua a 
mais frequentemente encontrada como agente causal de IFI; contudo a prevalência de 
leveduras não-albicans continua a aumentar. As taxas globais de susceptibilidade aos 
antifúngicos clínicos variaram entre 84 a 98% para a classe dos azoles e de 74 a 97% 
para a classe das equinocandinas.   
A partir desta recém formada coleção de leveduras determinámos a 
susceptibilidade in vitro aos fungicidas mais frequentemente utilizados na agricultura. 
 xxxii 
 
Alguns isolados de C. albicans, C. parapsilosis e C. glabrata suscetíveis aos 
antifúngicos clínicos e agrícolas foram selecionados para o estudo seguinte. Foi 
efetuado um ensaio de indução in vitro com um dos fungicidas mais utilizados em 
Portugal – Prochloraz (PCZ). Durante os 90 dias de indução os valores da concentração 
inibitória mínima (CIM) foram continuamente avaliados. Após os primeiros dez dias, o 
perfil de susceptibilidade de todas as espécies de Candida avaliadas revelou um valor de 
CIM entre 32 a 64 vezes superior ao inicial relativamente ao fungicida indutor. Candida 
glabrata foi a única espécie a desenvolver resistência cruzada aos antifúngicos clínicos 
após 60 dias de exposição ao fungicida agrícola. Estudámos os mais comuns 
mecanismos de resistência aos azoles e descobrimos que a pressão seletiva de PCZ 
desencadeou uma sobreregulação de genes que codificam para transportadores 
multidrogas, designados por ATP Binding Cassette, e o factor de transcrição, PDR1. Foi 
descrita uma mutação associada à resistência a azoles no factor de transcrição enquanto 
no gene ERG11 foram detectados vários “single nucleotide polimorfisms”. Estes 
resultados podem explicar a prevalência crescente de C. glabrata a nível global e o pior 
prognóstico associado a infecções causadas por esta espécie. O estudo seguinte recriou 
uma abordagem semelhante com A. fumigatus. Dois isolados clínicos e um ambiental 
foram expostos ao PCZ e esta exposição induziu alterações morfológicas e um aumento 
concomitante do valor de CIM ao PCZ. Após 30 dias de ensaio de indução, verificou-se 
para todos os isolados a aquisição de resistência cruzada aos antifúngicos de uso 
médico. 
Por último, procedemos a uma revisão acerca da origem da resistência aos 
azoles, desde a agricultura até ao contexto clínico, a nível nacional e internacional. 
Concluímos que a agricultura moderna, altamente dependente de fungicidas, se mostra 
essencial para manter a produção de alimentos nas quantidades necessárias. A fim de 
 xxxiii 
 
prevenir ou retardar o desenvolvimento da resistência cruzada, a comunidade agrícola 
deveria tomar algumas medidas, tais como rotação de fungicidas com diferentes modos 
de acção durante do cultivo, efectuar misturas de fungicidas mais eficientes, com 
múltiplos locais de inibição e excluir a utilização de monofungicidas. Além disso, 
estudos de vigilância deveriam ser implementados para acompanhar e monitorizar a 
distribuição de espécies e taxas de resistência a antifúngicos agrícolas e de uso médico. 
Em resumo, esta dissertação destaca o efectivo desenvolvimento de resistência 
cruzada aos antifúngicos entre a agricultura e a medicina em espécies clinicamente 
relevantes de Aspergillus e Candida. Ambos os fungos patogénicos mostraram que os 
fungicidas agrícolas são capazes de induzir resistência cruzada aos antifúngicos de uso 
médico. 
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General considerations  
 
From our contemporary perspective it is difficult to grasp the magnitude of 
achievements of our ancestors, mainly because we take the power of experimentation 
for granted. It is not easy, in the context of our modern scientific methodology, to 
imagine a time when information was sought largely by speculation guided by religious 
fantasy.  
Fungi were most probably discovered from early struggles to understand and 
overcome plant diseases and crop losses. There are several stories about early neolithic 
farmers that pointed out black dust over plant cultures and even noticed black-streaked 
cereal leaves. The first description of fungi was given by Giambattista della Porta as 
“tiny black seeds” over a plant named Phytognomonica in 1588. This vague information 
was only reviewed more than a century afterwards, and with the help of the microscope 
and by the illustrations of Hooke, Malpighi and Leeuvenhoek. However, only in 1729, a 
priest and botanist, Pier Antonio Micheli, describes a fungus in  “Nova Plantarum 
Genera”, that he named Aspergillus due to its microscopic morphologic similarity to an 
aspergillum - a brush or instrument used for sprinkling holy water [1]. 
On the other hand, yeasts can be considered man’s oldest industrial 
microorganism. It’s likely that man used yeast before the development of a written 
language. Hieroglyphics suggest that ancient Egyptians used yeast and the process of 
fermentation to produce alcoholic beverages and to leaven bread over 5,000 years ago. 
The biochemical process of fermentation that is responsible for these actions was not 
understood and undoubtedly looked upon by early man as a mysterious and even 
magical or miraculous phenomenon. It is believed that these early fermentation systems 
for alcohol production and bread making were formed by natural microbial 
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contaminants of flour, other milled grains or from fruit. Such microbial flora would 
have included wild yeasts and lactic acid bacteria that are found associated with 
cultivated grains and fruits. Also, it was not until the invention of the microscope 
followed by the pioneering scientific work of Louis Pasteur in the late 1860’s that yeast 
was identified as a living organism and the agent responsible for alcoholic fermentation 
and dough leavening [2-4].  
Nowadays, the importance of Aspergillus and Candida as human pathogens is 
undeniable. Based on population and disease demographics, it is estimated that globally 
over 1 billion people are afflicted with a fungal infection and 25 million are at great risk 
severe organ damage or death due to an invasive fungal infection (IFI) [5-8]. IFI caused 
by Aspergillus spp. and Candida spp. represent the most frequent life-threatening fungal 
infections in Europe [9-11]. Global models estimate that invasive aspergillosis affects 
more than 300.000 people and invasive candidosis more than 700.000 people per year, 
with mortality rates above 40% for both [8, 9]. 
 
 
Aspergillus fumigatus as a human pathogen 
 
Aspergillus species are widespread in the environment, growing on plants, 
decaying organic matter, in soil and in fresh or marine waters. Aspergilli are also found 
in indoor environments, in drinking water and dust. The diverse species belonging to 
Aspergillus genus are able to use a wide variety of organic substrates and adapt very 
well to a broad range of environmental conditions. They produce asexual conidia that 
readily become airborne and are highly stress tolerant, but can also produce 
environmentally persistent sexual ascospores [11]. 
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The genus Aspergillus contains 339 species divided into eight subgenera – 
Aspergillus, Fumigati, Circumdati, Candidi, Terrei, Nidulantes, Warcupi and Ornati – 
which in turn are subdivided into several sections or species complexes [12]. Only a few 
species, less than 40, are known to cause diseases in humans. Most invasive infections 
are caused mainly by members of A. fumigatus complex followed by A. flavus, A. 
terreus and A. niger species complex. Recently, the taxonomy of A. fumigatus has been 
revised by incorporating sequence-based information. In fact, A. fumigatus designation 
actually represents a section or complex of closely related species also referred as 
cryptic species that cannot be distinguished morphologically. A. fumigatus sensu stricto 
is the leading human pathogen while the sibling species of the complex have only been 
recognized as occasionally causing invasive aspergillosis, from 3 to 6% of the cases 
[13]. However, their actual prevalence may be underestimated because of the lack of 
recognition by conventional diagnostic approaches [14, 15]. Apart from A. fumigatus, 
the species of the complex Fumigati that are most frequently recovered in clinical 
specimens and associated with invasive fungal diseases are A. lentulus, A. udagawae, A. 
viridinutans, A. thermomutatus, A. novofumigatus and A. hiratsukae. Their limited 
pathogenic role compared to A. fumigatus may be explained by a lower thermotolerance 
and different profiles of secondary metabolites with decreased production of 
micotoxins, such as gliotoxin. Interestingly, these cryptic species exhibit decreased 
susceptibility to azoles and other medical antifungal agents [16, 17]. 
A. fumigatus is a saprophytic fungus that plays an important role in recycling 
environmental carbon and nitrogen in the composting procedure. It has thermotolerant 
properties which made it one of the few fungi able to handle with the high temperature 
during composting. A. fumigatus spp. exhibit typical morphological features that allows 
differentiation from other fungi. Macroscopically, they are characterized by rapid 
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growth, with a powdery texture and colored with various shades of green-blue, 
depending on the fungal strain and type of agar used. Microscopically, they are 
characterized by the presence of narrow, dichotomously branched septate hyphae. The 
conidiophores are a branch of the vegetative hyphae originating from the foot cell and 
ending with a vesicle. A. fumigatus sensu stricto exhibits columnar conidial heads with a 
flask-shaped vesicle, named phialides, and has rough conidia that are macroscopically 
green (Figure 1) [14, 18].  
Figure 1.  Macro and microscopic morphologic aspect of an Aspergillus fumigatus. 
 
Conidia of A. fumigatus that are inhaled by humans are usually eliminated by the 
innate immune system (neutrophils and macrophages) in immunocompetent individuals.  
However, depending on the virulence of the fungal strain, immunological status, and the 
host’s pulmonary structure and function, A. fumigatus may cause a spectrum of diseases 
that may range from allergic bronchopulmonary aspergillosis, chronic pulmonary 
aspergillosis to invasive aspergillosis (IA), which is a disseminated disease with a 
mortality rate of up to 90% in high-risk populations. 
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Allergic diseases caused by Aspergillus can be associated with asthma, sinusitis 
and alveolitis and occur following repeated exposure to conidia and/or Aspergillus 
antigens [19, 20]. In such cases, there is usually no mycelial colonization, and removal 
of the patient from the environmental source results in clinical improvement. Allergic 
bronchopulmonary aspergillosis (ABPA) is considered as an extreme form of A. 
fumigatus-induced asthma. In this case, the fungus grows saprophytically in the 
bronchial lumen, resulting in bronchial inflammation. The conidia trigger an IgE-
mediated allergic inflammatory response, leading to bronchial obstruction. Symptoms 
are recurrent fever, cough, wheezing, pulmonary infiltrates and fibrosis [21]. ABPA is 
observed in a small but numerically significant fraction of patients with asthma or cystic 
fibrosis (1–2% or 8–9% of the total, respectively) [22]. A locally invasive version of the 
disease, chronic necrotizing pulmonary aspergillosis, is mainly observed in humans 
with mild immunodeficiency or with a chronic lung disease [23]. Non-invasive forms of 
Aspergillus-induced lung disease include aspergilloma and ABPA [24]. IA currently 
constitutes the most common cause of pneumonia-related mortality in patients 
undergoing hematopoietic stem cell transplantation and is an important cause of 
opportunistic respiratory and disseminated infections in other immunocompromised 
patients [25, 26]. Globally, Aspergillus is estimated to cause health issues in millions of 
people annually, with IA accounting for approximately 200.000 annually [18, 27]. Early 
diagnosis as well as severity of underlying diseases impact the mortality rate of IA, 
which is acknowledged to be in the range of 30-50% [27], but such numbers are 
alarmingly high (>80%) when diagnosis is delayed or the causative agent is resistant 
[28]. 
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Candida as a human pathogen 
 
Candida organisms are present not just in the usual human microbioma of 
mucosal oral cavity, gastrointestinal tract and vagina as commensals but are also 
ubiquitous in the environment [29, 30], Table 1.  
 
Table 1. Candida habitat. (Table from Schauer and Hanschke [30]). 
 
 
The genus includes a very large heterogeneous group of organisms, while only a 
few different Candida species are known to be aetiological agents of human infection. 
Only five species account for 92% of cases of candidemia: C. albicans, C. glabrata, C. 
tropicalis, C. parapsilosis, and C. krusei. However, its distribution varies in population-
based studies conducted in different geographical areas. C. albicans is the most frequent 
species, but considerable differences are found between the number of cases caused by 
C. glabrata and C. parapsilosis. Studies from Northern Europe and the United States of 
America (USA) reported a high number of cases caused by C. glabrata, whereas studies 
from Portugal, Spain and Brazil demonstrated a lower number of cases caused by C. 
SOURCE(S) OF ISOLATES % OF TOTAL a 
Plants, leaves and flowers 21 
Fruits and juices 9 
Beer and wine 4 
Other food items 8 
Soil and sludge 11 
Water 6 
Air 1 
Insects 12 
Animals 8 
Humans 16 
Machines 3 
a Frequency of isolation from source(s) relative to other sources. 
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glabrata and a higher number of cases attributed to C. parapsilosis [31]. Globally, the 
frequency of C. albicans is decreasing, while that of C. glabrata and C. krusei is stable, 
and C. parapsilosis and C. tropicalis is increasing. In most individuals, C. 
albicans resides as a lifelong, harmless commensal [32]. However, under certain 
circumstances, C. albicans can cause infections that range from mucocutaneous 
overgrowth to life-threatening systemic infections [33]. The growing population of 
immunocompromised patients receiving intravenous catheters, total parenteral nutrition 
or invasive procedures and the increasing use of broad-spectrum antibiotics, cytotoxic 
chemotherapies and transplantation contribute to the increase of such infections [34]. 
The pathogenicity of Candida species is attributed to certain virulence attributes, such 
as the ability to evade host defenses, adherence, biofilm formation (on host tissue and 
medical device surfaces) and the production of tissue-damaging hydrolytic enzymes 
such as proteases, phospholipases and haemolysin [33].  
Candida spp. remain the most common cause of IFI, and the incidence of 
candidemia, which is estimated at 72.8 cases per million inhabitants/year, clearly 
exceeds that of invasive aspergillosis and mucormycosis [35]. Indeed, Candida spp are 
the fourth most common agent of hospital-acquired systemic infections in the United 
States, with crude mortality rates of up to 50% [34]. C. albicans can cause two major 
types of infections in humans: superficial infections, such as oral or vaginal candidosis, 
and life-threatening systemic infections. Candidemia has an attributable mortality of 
15–35% for adults and 10–15% for neonates and early and late mortality (7 days and 30 
days after diagnosis) which is 13% and 30%, respectively [36]. Whereas early mortality 
is associated with factors such as appropriate antifungal therapy and early removal of 
central venous catheters, late mortality is associated with factors related to the baseline 
condition of the host [31]. The mortality rate is closely correlated with a delay in the 
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initiation of appropriate antifungal treatment. Inappropriate treatment includes absence 
of antifungal treatment, a delay in initiation, but also the use of an inactive agent due to 
antifungal resistance, which is a growing problem [37-39].  
 
 
Bridging Aspergillus and Candida 
 
The total number of eukaryotic species on Earth was recently estimated in 8.7 
million, with fungi making up approximately 7% (611.000 species) [40]. Among fungi, 
nearly 600 species are human pathogens [5, 41]. This relatively small group 
encompasses fungi that cause relatively mild infections of the skin (e.g., dermatophytes 
and Malassezia species), fungi that cause severe cutaneous infections (e.g., Sporotrix 
schenkii) and fungi that have the potential to cause life-threatening systemic infections, 
being Aspergillus and Candida, by far, the most significant pathogens. It is recognized 
that most invasive candidosis episodes are related to concomitant colonizing Candida 
organisms; although, it remains unclear what is the extent of colonizing fungal 
microbiota that is influenced by exogenous Candida [34]. Only a few studies have 
investigated the potential concern of an exogenous source and described the occurrence 
of  antifungal resistant Candida organisms on fruit and vegetables from plantations 
displaying cross-resistance to clinical azoles [42, 43]. In contrast, the current situation 
of resistant clinical infections caused by A. fumigatus potentially originating from the 
environment is now a worldwide concern [28, 44, 45].  
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Antifungals and susceptibility testing 
 
The development of antifungals is challenging since fungi are eukaryotes like 
the human hosts they infect. Therefore, there are few distinct targets that can be used for 
drug development. There are three major classes of antifungal drugs available to treat 
invasive fungal infections. The first generation of antifungals was implemented in the 
late 1950s with intravenous formulations of polyenes such as Amphotericin B (AMB). 
Polyenes target ergosterol - a component that is analogous to cholesterol in mammalian 
cell membranes. Therefore, these compounds exhibit high toxicity in humans [46]. A 
key breakthrough occurred two decades later with the advance of azoles as intravenous 
and oral formulations. The azoles target the biosynthetic pathway of ergosterol by 
inhibiting an early-phase enzyme called lanosterol 14α-demethylase, leading to the 
accumulation of sterol intermediates, making cells vulnerable to membrane damage due 
to its toxicity. The fungistatic nature of azoles and its interaction with the cytochrome 
P450 enzymes make them less appealing in patients undergoing multidrug therapies. 
The development of echinocandins tried to overcome azole limitations in 2001. These 
drugs are semi-synthetic derivatives of a cyclic lipophilic peptide isolated from Glarea 
lozoyensis. Echinocandins are fungicidal drugs that block cell-wall synthesis by 
inhibiting β-(1, 3)-D-glucan synthase [47].  
Several in vitro assays have been developed and standardized in order to test the 
susceptibility of a microorganism, and the result is expressed as the minimal inhibitory 
concentration (MIC) of a determined antifungal – conveying the concentration of a drug 
which is required to kill or inhibit the growth of the fungus [48]. Two major protocols 
are currently used, brought by the two major antifungal susceptibility testing 
subcommittees: CLSI, Clinical Laboratory Standards Institute [49-51] and EUCAST, 
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European Committee on Antimicrobial Susceptibility Testing. EUCAST has set forth a 
species-specific approach for the most prevalent pathogenic yeasts (E.Def 7.2) [52] and 
moulds (E.Def 9.2) [53] and established clinical breakpoints. The EUCAST broth 
dilution method is similar to that of CLSI with modifications concerning some of the 
test parameters such as inoculum preparation and inoculum size. The MIC reading 
method is visual in CLSI assay and spectrophotometric in EUCAST guidelines. Such 
breakpoints can be used to determine whether an organism is susceptible (S), 
intermediate (I) or resistant (R) to a drug, which in turn may be translated to clinical 
susceptibility. No official breakpoints exist for agricultural fungicides. Consequently, to 
achieve a clear perspective of what is more or less susceptible to a determined 
fungicide, a large number of in vitro susceptibility tests is necessary. 
 
 
Antifungal resistance  
 
Some fungal species are not disturbed by specific antifungal agents, independently 
of the concentration of the drug. The absence of drug activity in a species that was not 
pre-exposed to that agent is known as intrinsic resistance. Taking as example the 
response of Candida and Aspergillus spp. to fluconazole, it is known that wild type C. 
albicans is susceptible to fluconazole, whereas A. fumigatus and C. krusei are 
intrinsically resistant to this drug [54]. 
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Mechanisms of antifungal resistance fall into distinct categories, including 
decrease of effective drug concentration (A), drug target alterations (B), and metabolic 
bypasses (C) – representative illustration in Figure 2. 
 
Figure 2. Schematic representation of the principal antifungal resistance mechanisms.  
 
Cells can resist to the drug activity simply by pumping the drug out of them 
(Figure 2 (A)). These resistance mechanisms can be mediated by several efflux 
transport systems, including adenosine triphosphate-binding cassette (ABC) transporters 
and transporters of the major facilitator superfamily (MFS). Genome sequencing has 
allowed the identification of several different types of transporters: C. albicans is 
predicted to contain 28 ABC proteins and 96 potential MFS transporters, whereas C. 
glabrata displays at least 18 ABC transporters and 33 MFS transporters [55]. Larger 
numbers of ABC and MFS proteins are found in A. fumigatus (45 and 275, respectively) 
[56]. Despite the differences among the ABC transporters sub-families, all of them 
contain membrane spanning domains and use adenosine triphosphate (ATP) hydrolysis 
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for drug transport. MFS transporters are transmembrane proteins, which use the 
electrochemical proton-motive force to mediate drug efflux. MFS are co-players in 
multidrug resistance (MDR) (MFS–MDR transporters) as proton antiporters and are 
classified into two groups: H+ antiporter-1 DHA1 family and H+ antiporter-2 DHA2 
family [57].  
Only ABC transporters of the pleiotropic drug resistance (PDR) class are relevant 
for antifungal drug resistance. In C. albicans, the PDR class comprises the major 
transporters involved in azole resistance, including CDR1 and CDR2 - the upregulation 
of both mediates azole resistance by enhanced drug efflux and reduces azole 
accumulation in some C. albicans clinical strains. For C. glabrata the ABC transporters 
known to be involved in azole resistance by their upregulation are CgCDR1, CgCDR2, 
CgSNQ2 genes [55]. In A. fumigatus, it is still not clear the association between azole 
resistance and transporter upregulation. Slaven and colleagues report the upregulation of 
the ABC transporter atrF in an azole-resistant clinical isolate but this could not be 
definitely attributed as the cause of resistance [58]. The only known transporter gene 
with a direct role in azole resistance in A. fumigatus is abcA gene, renamed cdr1 [59]. 
Also, AfuMDR3 - a MFS transporter was found to be upregulated also in a collection of 
A. fumigatus itraconazole (ITC)-resistant laboratory-derived mutants [60].  
On the other hand, MFS involved in the development of azole resistance in clinical 
isolates are restricted to MDR1 from C. albicans and C. dubliniensis. MDR1 is 
upregulated in specific strains, which results in enhanced azole efflux [55]. 
Upregulation of ABC and MFS transporters is mediated by specific regulators in 
resistant fungal pathogens. In C. albicans, CDR1 and CDR2 are known to be regulated 
by a zinc cluster finger transcriptional regulator called TAC1 and MDR1 by another 
regulator called MRR1 [61, 62]. Gain of function mutations (GOF) in these regulators 
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have been described, which confer a hyperactivation state that does not require 
additional stimulation, thus explaining the inherent high expression levels of the 
transporters in drug-resistant isolates [62]. Other transcriptional regulators of drug 
transporters relevant to azole resistance, such as PDR1, have been described in C. 
glabrata [63]. Another resistance mechanism can be the increasing of the number of 
drug targets, making the effective drug concentration insufficient to saturate all target 
molecules. For example, ERG11 upregulation has been associated with azole resistance 
in C. albicans. This transcriptional regulation is mediated by a zinc cluster finger 
transcription factor called UPC2. As in the case with other drug resistance 
transcriptional regulators, GOF mutations in UPC2 have been described and result in 
upregulation of various genes, among which is ERG11 [62]. Upregulation of Cyp51A is 
also recognized in azole-resistant A. fumigatus isolates; however, the upregulation is 
mediated by duplication of 34- and 42-bp elements (trans-regulation) in the Cyp51A 
promoter. This duplication is associated with specific Cyp51A mutations (L98H, 
Y121F/T289A) [64]. 
Drug target alterations have been reported for azoles and echinocandins (Figure 
2 (B)). The targets of these two drugs are a 14α-lanosterol demethylase and a β-1,3 
glucan synthase, respectively. Lanosterol demethylase is encoded by ERG11 in C. 
albicans and by Cyp51A and Cyp51B in A. fumigatus. Mutations in ERG11, resulting in 
non-synonymous amino acid substitutions that are present in azole-resistant C. albicans 
isolates, are numerous and were shown to decrease the affinity of the target to azoles 
[55]. Mutations in lanosterol demethylase genes from azole-resistant A. fumigatus 
isolates have been only reported in Cyp51A until now. Single Cyp51A mutations are 
sufficient to confer high level resistance to azoles in this species. As in the case of 
ERG11, Cyp51A mutations have different impact on MICs that depend on the azole 
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structure [64, 65]. Decreased affinity to the target is also recognized in the case of 
echinocandins. β-1,3 glucan synthases are encoded by FKS genes in different fungal 
species. Candida parapsilosis family, including C. parapsilosis, C. orthopsilosis, and C. 
metapsilosis exhibit intrinsic low susceptibility to echinocandins. FKS1 genes in these 
species exhibit a natural polymorphism, enabling decreased affinity of the β-1,3 glucan 
synthase to echinocandins. However, this natural FKS1 polymorphism of these species 
has less impact than those resulting from mutations, since these Candida species still 
respond to echinocandin therapy [66]. 
Metabolic bypasses occur when some metabolic pathways are impaired by loss 
or significant decrease of specific functions (Figure 2 (C)). For example, resistance to 
azoles can be mediated by loss-of-function mutations in the gene ERG3 that encodes a 
sterol Δ5,6 desaturase. If active, the gene product converts 14α-methylated sterols that 
arise from azole exposure into a toxic 3,6-diol derivative. Fungi unable to produce this 
metabolite acquire azole resistance. Several studies have reported ERG3 loss-of-
function mutations to account for azole resistance. Due to a deficiency in ergosterol 
biosynthesis, these isolates can be, however, less competitive than wild type isolates. As 
a result of loss-of-function of ERG3 in specific mutants, ergosterol is absent from cell 
membranes - this way, the mutants escape the toxic effect of AMB [61, 62]. Until now 
it is quite clear that while the variety of resistance mechanisms may be equally complex 
as for Candida species [31], about 90% of azole resistance cases in A. fumigatus have so 
far, been linked to genetic changes in CYP51A gene [65, 67, 68]. 
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Dilemmas in clinical management  
 
The susceptibility profile of the fungal pathogen is only one of the factors that 
contributes to the clinical outcome. Several factors, as site of infection, fungal burden, 
strain acquisition with virulence attributes and underlying disease - have been identified 
as key determinants [69]. However, it is expected that patients infected with a fungal 
isolate for which an antifungal MIC is higher than average, or within the MIC range  
categorized as resistant for that organism, will fail antifungal treatment [5]. This has 
partly been attributed to the growing population of pathogenic fungi with emerging 
resistance to antifungal therapy, which potentially compromises the management of 
infected patients [70, 71]. In most cases, a reduced in vitro fungal susceptibility to 
azoles and/or echinocandins can be a sign of the acquisition of a particular resistance 
mechanism. Strategies using antifungal combinations or adjunctive agents that 
maximize the efficacy of existing antifungals may somewhat limit treatment failures 
[72, 73] . New therapeutic approaches, including antifungal agents with novel 
mechanisms of action are under investigation [74-78]. 
Thus, clinical management of antifungal-resistant Candida and Aspergillus 
diseases remains difficult. Multi-azole resistance among A. fumigatus is a current 
medical problem and, indeed, the high number of international reports addressing 
azole resistance among A. fumigatus reflects a particular focus on this emerging threat 
[28, 44, 45, 64]. This is also verified with the increasing number of co-resistant C. 
glabrata to both azoles and echinocandins [79].  
Another very relevant dilemma responsible for a very high mortality and 
morbidity in IFI can be attributed to the delay in diagnosis and institution of 
appropriate therapy [73]. Diagnosis of a fungal pathogen deep-seated in the tissues or 
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organs is difficult and is often driven by clinical suspicion. The detection of IFI is only 
apparent following the dissemination of cells from the invaded tissues, organs or 
biofilms. Current diagnostic practices involve histopathology analyses and cultures. 
Histology of biopsy samples lacks specificity, sensitivity and taxonomic information 
[80]. Fluid samples such as blood, alveolar lavage, and sputum or tissue counterparts 
are usually first cultured on non-selective medium to maximize microbial counts for 24 
hours and later using genus-specific agar plates [36, 81]. Novel molecular methods on 
antigen detection do not add much in terms of diagnostic efficacy [80, 82]. However, in 
patients suffering from life-threatening fungal infections, institution of appropriate 
(type and dose) antifungal therapy becomes of critical importance for the outcome. In 
such circumstances, the clinician has to choose between time-consuming confirmatory 
tests that may delay therapy and broad spectrum antifungals institution. Considerable 
challenges also arise when a clinician deals with non-sterile samples, which pose 
difficulties in differentiating colonization from contamination. Such scenarios demand 
a deep knowledge in recognizing disease signs and symptoms [47, 54, 69, 73]. Even 
owing to such uncertainties, clinical samples are often not subjected to in vitro 
antifungal susceptibility testing as a part of the diagnosis. Despite that techniques being 
time consuming and “low-throughput”, it is known that early diagnosis and 
concomitant targeted therapy has proven to significantly improve patient outcome [54]. 
The last and most recent clinical dilemma arises from advances in phylogenetic 
analyses and molecular methods that revealed the important diversity of Aspergillus 
species within the section Fumigati [13, 16]. Some clinical isolates may actually be 
misidentified as A. fumigatus by conventional diagnostic methods, which may result in 
inappropriate antifungal therapy because of the decreased susceptibility of those cryptic 
species to many antifungal agents [17]. Azole resistance among A. fumigatus isolates is 
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an emerging problem, which has been highlighted by multiple recent reports 
throughout the world, but its prevalence is still low [83-85]. Therefore, in the case of an 
azole-resistant IA, clinicians should suspect that a sibling species of A. fumigatus may 
be the causal agent. Slow or poor sporulation is usually the first hint that should alert 
the microbiologist. Sequencing of the ITS region, followed by targeted sequencing of 
the beta-tubulin or calmodulin genes seems to date the most appropriate method for 
reliable species identification. However, these procedures are not available in most 
institutions. Matrix assisted laser desorption ionization-time to flight mass spectrometry 
(MALDITOF MS) may be a very convenient alternative approach for the rapid 
detection of A. lentulus and other A. fumigatus-related species, but further 
investigations for standardized sample treatment procedures of filamentous fungi and 
spectra characterization are required. Antifungal susceptibility testing may also be 
useful because of the unpredictable susceptibility profile of these species. However, 
results should be interpreted with caution because of the lack of clinical breakpoints 
and the absence of data correlating MICs with clinical outcomes [13, 16, 17].  
 
 
The use of fungicides in anthropogenic activities 
 
Fungal diseases have a significant economic impact on plant yield and quality. 
Thus, managing such diseases is essential for most crops. A fungicide is a specific type 
of pesticide that controls fungal disease by specifically inhibiting or killing fungi that 
cause disease. Fungicides are used also to prevent or to ease the problem of postharvest 
spoilage of plants and fruits [86, 87]. In agriculture, various compounds have been 
described for fungicide activity against a broad range of fungi. Among them, azoles are 
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widely applied, besides dithiocarbamates, strobilurins and benzimidazoles [88-90]. 
Azoles are used in wood and textile preservation and human and animal health 
products, but their major use is in agriculture, horticulture and prevention of post-
harvest losses. The imidazole imazalil was introduced in the late 1970s and is still used 
today in wax formulations applied as post-harvest treatments to citrus and pome fruits, 
bananas and seed potatoes. Another imidazole, PCZ), was introduced a few years later, 
primarily for control of cereal eyespot (Tapesia sp.) and is still widely used today. 
Several triazoles were introduced in the 1980s, especially for control of cereal and fruit 
diseases, and although they are still in use in some markets, they have largely been 
replaced by more effective products, including propiconazole (1990), tebuconazole 
(1992), difenconazole (1994) epoxiconazole (1994) and bromuconazole (2000) [91]. All 
azole fungicides are of synthetic origin and are characterized by the presence of an 
aromatic five-membered heterocycle. These include triazoles (two carbon atoms and 
three nitrogen atoms), imidazoles (three carbon atoms and two nitrogen atoms), and 
triazoles (three carbon atoms, one nitrogen atom and one sulfur atom). The 
characteristics of the azole rings, which are distinguished by the number of nitrogen and 
sulfur atoms, change the physical and chemical properties, toxicity, and therapeutic 
efficacy of these compounds [90]. Therefore, the addition of different substitutes to the 
pristine 1,2,4-triazole molecule influences its fungicide or fungistatic effect. Around a 
third of all fungicides used for the protection of crop yields include triazoles, among 
which more than 99% are demethylation inhibitors (DMIs) [92]. Triazoles affect the 
biosynthesis of ergosterol, a fundamental component of the fungal cell plasma 
membrane. The main target of antifungal azole drugs is lanosterol 14-demethylase 
(Erg11 protein), a cytochrome P450 enzyme that is involved in the conversion of 
lanosterol to 4,4-dimethylcholesta-8(9),14,24-trien-3-ol. The azole agents link to this 
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enzyme using the aromatic five-membered heterocycle and thereby inhibit the 
cytochrome P450 catalytic activity. The absence of ergosterol and the increase of 
intermediate compounds alter fungal membrane integrity as well as cell morphology, 
which inhibits fungal growth [93]. 
Thousands of tons of azoles are sold and applied annually in crop fields [87, 91, 
94]. According to the instructions of manufacturers, the quantities applied should be 
about 10 mg of azoles on 1 m2 of plant surface. Usually, multiple applications per year 
are needed if, as might be the case during rainy seasons [91]. Azoles exhibit several 
advantages when compared with other fungicides. They are not expensive and show a 
broad spectrum of antifungal activity. They are effective against mildews and rusts of 
grains, fruits, vegetables, and ornamentals; powdery mildew in cereals, berry fruits, 
vines, and tomatoes; leaf spots and flower blights in flowers, shrubs, and trees [95, 96]. 
They are used not only in preventing but also for the treatment of plant infection. 
However, some azoles could remain active during several months in certain ecological 
niches, as in soil and water, over months with only slight changes in their chemical 
structures, like the loss of some side chains [91]. Azole residues have been detected in 
fruits and plants for human consumption, for example, in strawberry [97], grapes [98], 
and peppermint [99], with values up to 0.5-0.8 mg/kg. The most considerable amount of 
azole residues has been reported in apples, reaching up to 2.16 mg/kg [100].  
The Fungicide Resistance Action Committee (FRAC) is a technical group 
maintained by the industry, which was developed at an industry seminar in Brussels in 
1981. Nowadays, FRAC has several delegations not only in Europe but also in USA, 
Latin America (Brazil) and Asia (Japan). Its aim is to provide guidelines for the 
management of fungicide resistance, trying to estimate the baseline resistance level of a 
determined fungicide prior to its commercial use. Also, during fungicide 
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commercialization, this committee provides periodically information concerning the 
risk of resistance development [101, 102]. The acquisition of resistance to azoles by 
plant pathogenic fungi is complex and it is generated slowly and in small steps. 
Although it has been considered that the risk of selecting azoles-resistant strains is low, 
there have been reports claiming that some plant pathogenic fungi have indeed acquired 
azole resistance [90]. It is anticipated that the excessive use of azoles in agriculture 
would not only influence the plant pathogenic species but also would certainly attack 
susceptible species of the saprophytic flora [103].  
One possible consequence of such a disequilibrium in the ecology of the fungal 
flora is that some naturally existing human fungal pathogens may survive and multiply. 
Those strains which have acquired azole resistance will particularly benefit from the 
selective pressure. This could increase the risk of the contact of humans with such 
resistant fungal organisms.  
 
 
The impact of agricultural antifungals upon clinical antifungals  
 
Triazole fungicides, in particular, are used globally for the control of fungal 
diseases both in humans and plants. Also, the resistance to triazoles among fungi is an 
emergent issue both in agriculture and medicine. The non-rational use of fungicides 
with site-specific mechanisms of action, such as the triazoles, may increase the risk of 
antifungal resistance [92]. In the medical field, the emergence of resistant fungi has 
been related to the intensive and recurrent therapeutic use of a limited number of 
triazoles for the treatment and prophylaxis of many mycoses. Similarities in the mode of 
action of triazole fungicides used in these two fields may lead to cross-resistance, thus 
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expanding the spectrum of resistance to multiple fungicides and contributing to the 
perpetuation of resistant strains in the environment.  
The number of antifungals available in the medical field for the treatment of 
systemic infections is relatively limited compared to those used for controlling diseases 
in plants, which is mainly due to problems related to erratic efficacy, drug toxicity, and 
intrinsic resistance. The first generation of triazoles for human therapy included 
fluconazole (FLC) and ITC. The second generation is represented by voriconazole 
(VRC) and posaconazole (PSC), which proved to be less toxic, safer, and with a broader 
spectrum of activity, including activity against fungi that were resistant to the previous 
generation [76, 104]. Presently, isavuconazole, ravuconazole, and albaconazole are 
being investigated in phase III clinical trials as extended-spectrum triazoles with 
fungicidal activity against a wide number of clinically important fungi [105]. 
In the medical field, the first report of resistance of A. fumigatus isolates was almost 
three decades ago. In 1989, the first ITC resistant isolate was recovered from two 
American patients with invasive aspergillosis that were under ITC therapy [106]. 
Afterwards, two studies in Europe also found ITC resistant isolates after prolonged 
azole therapy: in 2002 a Dutch study assessing the in vitro susceptibility of isolates 
recovered from 1945 to 1998 found three ITC resistant isolates recovered in 1997 from 
a lung transplant recipient [107]; a French study found 4 ITC resistant isolates in 1999 
[108]. Later, in 2007, a Dutch study found 4 azole resistant isolates from patients who 
had never received azole therapy [109]. 
It is known that, sometimes, the emergence of resistance has some kind of 
repercussion upon other capabilities of the cell corresponding to the sacrifice of an 
adaptive feature – impairing the so called fitness of the fungal cell [110]. Nevertheless, 
concerning A. fumigatus the ability to survive in very different environmental 
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conditions, the widespread asexual sporulation, the hydrophobicity of spores and the 
easy airborne dispersibility, were not affected and altogether probably empower the 
global spread of resistance from its centers of origin [54]. Therefore, we have witnessed 
several reports claiming that exposure of environmental fungi to triazole fungicides may 
cause shifts from susceptible to resistant populations, which especially in the absence of 
adaptive costs, may facilitate its spread into diverse environments and geographical 
areas [111]. Subsequently, the emergence of fungi in the medical field otherwise 
harmless to humans may become a reality – for instance, the fungus Colletotrichum 
graminicola that causes anthracnose of corn plants is now an emerging pathogen in 
humans - such as the zygomycetes and other hyaline filamentous fungi [112]. In fact, 
the initial hypothesis suggested by studies conducted in the Netherlands [67, 113] that 
the mechanism that may be leading to resistance is the selective pressure of fungicides 
used in agriculture is now corroborated by studies conducted a little all over the world 
[114]. The development of cross-resistance to triazoles and the low number of triazoles 
recommended for human therapy in comparison to the higher number of triazoles used 
in agriculture may impair triazole efficacy for human therapy [115]. Cross-resistance to 
triazoles may spread either way: from resistant plant pathogenic yeast and moulds to 
clinical antifungals and/ or from clinical isolates of yeasts and filamentous fungi 
resistant to fungicides [42, 116-119]. 
The increasing reports that the use of azoles in the environment is driving the 
development and spread of resistance to medical antifungals is so strong that, in 2013, 
the European Centre for Disease Control (ECDC) published a risk assessment report 
about this topic and also summarized several evidences for the environmental origin of 
azole resistance [92]:  
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1) Azole resistant A. fumigatus isolates have been recovered from naïve patients 
(i.e. with no history of previous azole exposure) [120];  
2) Azole resistant A. fumigatus isolates with a dominant resistance mechanism and 
only  two variants TR34/L98H or TR46/Y121F/T289A [28];  
3) From this dominant mechanisms, both variants TR34/L98H and 
TR46/Y121F/T289A are stable and are the most commonly found mechanism among 
clinical and environmental isolates. In other studies involving a high proportion of azole 
treated patients with chronic forms of aspergillosis, as in the United Kingdom (UK), a 
more heterogeneous population of CYP51A variants exists. Therefore, it is assumed that 
the in vivo selection of resistance may result in a more diverse panel of resistance 
mutations in CYP51A [121]; 
4) Both TR34/L98H and TR46/Y121F/T289A resistance mechanisms associate to 
two independent genetic events (mutations and a tandem repeat), which have not been 
found previously in any case of in vivo resistance development but are present in azole 
resistant plant pathogenic filamentous fungi [67, 122];  
5) Both environmental and clinical isolates harboring TR34/L98H cluster 
genetically together and are distinct from any other susceptible wild-type isolate [123, 
124];  
6) The TR34/L98H isolates are cross-resistant to several triazole fungicides which 
were introduced in the agriculture just few years before the first detection of a 
TR34/L98H isolate in 1998 (tebuconazole, propiconazole, difenoconazole, 
epoxiconazole and bromucazole) [125, 126];  
7) Triazole fungicides display similar molecular structure and mode of action as 
clinical azoles. Moreover, they have been shown to induce tandem repeats in CYP51A 
in vitro, conferring reduced susceptibility to clinical azoles [125].  
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The use of azoles in the environment will be difficult to restrict, unless scientists 
raise better public and political awareness about this problem. Vulnerable patients can 
become exposed and, if these hosts develop Aspergillus disease, the medical azoles are 
no longer effective due to the structural similarity of the molecules. Still, it is unclear 
how and where resistance develops in the environment and which form of application of 
fungicides are inducing the development of resistance most successfully [127]. 
It has not been routine practice in microbiological laboratories to carry out in vitro 
susceptibility testing of filamentous fungi. However, this has started to change in the 
last few years and presently many centers now test A. fumigatus for resistance to azoles. 
As a result, it has become evident that azole resistance has a potentially global 
distribution, and is a worldwide problem [115]. Isolates harboring one of these two 
dominant mutations associated with the environmental route are being found in Europe, 
already including a considerable number of countries like Belgium, France, Spain, 
Denmark, Italy, The Netherlands, Norway, Germany, Ireland, UK, Poland, Romania 
and Austria [114, 115]. Reports about these resistance mechanisms are also found 
outside Europe: in Turkey, Iran, Kuwait, Japan, China, Taiwan, Pakistan, India, 
Tanzania and Australia, mainly associated with TR34/L98H but increasingly also with 
TR46/Y121F/T289A [114]. Also, recently, in USA and Colombia, azole resistance 
owing to environmental mutations was reported recently [128-130]. In Portugal, in 2014 
a study from Lago et al, tried to the answer the question: “Does fungicide application in 
vineyards induce resistance to medical azoles in Aspergillus species?”; however, they 
did not have a conclusive response since there was not any decrease in the susceptibility 
of the Aspergillus isolates to the tested azoles tested during the period when vineyards 
were treated with fungicides. They have found a few environmental isolates of 
Aspergillus spp. resistant to azoles but they could not prove that the use of fungicides 
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were responsible for it [117]. Recently, Sabino et al provided a study upon the clinical 
antifungal susceptibility of 175 Aspergillus isolates from both clinical and 
environmental sources, describing that species identity and site of isolation influences 
the clinical antifungal susceptibility profiles. Differences were found in clinical isolates 
showing higher susceptibility to AMB and POS while isolates recovered from the 
hospital environment showed to be significantly less susceptible to the same clinical 
antifungals [131]. A similar study previously published by Araújo et al. some years ago, 
involving 446 isolates belonging to the Aspergillus genus; in contrast, they found that 
resistant isolates to clinical antifungals from both environment and clinical settings were 
very uncommon. Only a few non-fumigatus clinical isolates revealed significantly 
higher MIC values to AMB, ITC and CSF. In fact, neither clinical nor environmental 
isolates of A. fumigatus showed to be resistant to any of the tested clinical antifungals 
[132]. To the best of our knowledge, there is no study in Portugal assessing the genetic 
mechanisms in Aspergillus fumigatus responsible for azole resistance from both clinical 
and environmental sources nor a study revealing the prevalence of infections caused by 
resistant filamentous fungi.  
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Outline of this thesis 
The main aim of this thesis was to investigate whether agricultural antifungals 
may have an impact upon these ubiquitous organisms (Aspergillus and Candida) 
namely whether resistance may develop and jeopardize the susceptibility to clinical 
antifungals. In order to know the clinical yeasts isolate distribution and susceptibility to 
clinical antifungals a national surveillance study was conducted; the results are 
described in chapter 2. Clinical Candida isolates obtained from chapter 2 were 
screened and a few were selected to assess the in vitro induction of resistance to an 
agricultural azole and the hypothetical development of cross-resistance to clinical 
azoles; this study is detailed in chapter 3. A similar approach was followed with 
isolates of Aspergillus fumigatus; the results are shown in chapter 4. In chapter 5 we 
reviewed the origin of azole resistance, from agriculture to clinical settings. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
2 Species distribution and in vitro 
antifungal susceptibility profiles of 
yeast isolates from invasive infections 
during a Portuguese multicenter survey. 
 
 
 
 
 
 
 
 
 
 
I. Faria-Ramos, J. Neves-Maia, E. Ricardo, J. Santos-Antunes, A. T. Silva, S. 
Costa-de-Oliveira, E. Cantón, A. G. Rodrigues and C. Pina-Vaz 
Eur J Clin Microbiol Infect Dis. 2014 Dec;33(12):2241-7 
Species distribution and in vitro antifungal susceptibility profiles of yeast isolates from 
invasive infections during a Portuguese multicentre survey 
 
30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Species distribution and in vitro antifungal susceptibility profiles of yeast isolates from 
invasive infections during a Portuguese multicentre survey 
 
31 
 
ABSTRACT   
This is the first Portuguese multicenter observational and descriptive study that 
provides insights on species distribution and susceptibility profiles of yeast isolates 
from fungemia episodes.  
Ten district hospitals across Portugal contributed by collecting yeast isolates 
from blood cultures and answering questionnaires concerning patients’ data during a 
twenty-four month-period. Molecular identification of cryptic species of Candida 
parapsilosis and C. glabrata complex was performed. The susceptibility profile of each 
isolate, considering eight of the most used antifungals, was determined. Both CLSI and 
EUCAST protocols were applied.  
The incidence of 240 episodes of fungemia was 0.88/1000 admissions. Fifteen 
different species were found, with Candida albicans (40%) as the most prevalent 
followed by C. parapsilosis (23%) and C. glabrata (13%). Most isolates were recovered 
from patients admitted at surgical wards or Intensive Care Units with 57% being males 
and 32% being of the age between 41 to 60 years. For both CLSI and EUCAST, the 
overall susceptibility rates ranged from 74% - 97% for echinocandins and 84% - 98% 
for azoles. Important resistance rate discrepancies between protocols were observed in 
C. albicans and C. glabrata for echinocandins and in C. parapsilosis and C. tropicalis 
for azoles. Death associated with fungemia occurred in 25% of the cases with more than 
half of C. glabrata infections being fatal.  
The great number of Candida non-albicans is noteworthy despite a relatively 
low antifungal resistance rate. Studies like this are essential to improve empirical 
treatment guidelines. 
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INTRODUCTION  
The increased incidence of fungemia represents a clinical problem and its impact 
has significantly risen during the last twenty years [133]. Fungemia is an important 
cause of morbidity and mortality, being related to longer hospital stays and high 
economic costs. Candida albicans still remains the leading cause of fungemia 
worldwide [134]; Candida parapsilosis, Candida glabrata and Candida tropicalis 
occupy places two to four, varying according to region. Due to the medical relevance of 
fungemia and its strong association with unfavorable outcomes, epidemiological 
surveillance studies are urgently needed in order to evaluate species’ geographic 
distribution and potential changes in susceptibility profiles. In addition, there is a 
limited number of therapeutic options, with the main class of drugs (azoles) being 
controversially used for prophylaxis, possibly leading to decreased susceptibility and 
the selection of non-albicans species [10, 38, 135]. Regarding the susceptibility testing 
there are currently two independent organizations suggesting standard protocols: the 
CLSI and EUCAST [49, 50, 136]. Their protocols differ not only on the laboratory 
execution and interpretation but also with respect to the breakpoints proposed for each 
species / drug combination, leading to discrepancies on the categorization of the isolates 
as susceptible or resistant [137]. The aim of this study was to provide an overview of 
blood-borne yeast infections in Portugal and to evaluate the susceptibility profiles 
provided by both protocols, CLSI and EUCAST. 
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MATERIALS AND METHODS 
 
Study design Ten hospitals from northern (four), central (two) and southern (four) 
regions of Portugal accepted to participate in this study, providing isolates collected 
from patients with fungemia from January 1st 2010 and December 31st 2011. All 
hospitals enrolled in this study were able to admit adults, children and neonates. From 
those, two hospitals had more than 1000 beds, 3 had between 600 and 1000 beds and 5 
had less than 600 beds. All were asked to collect and send the strains to the 
Microbiology Department of the Faculty of Medicine of the University of Porto, where 
the study was conducted. In addition, a questionnaire regarding patient’s clinical and 
demographic data was also sent.  
 
Definitions The start of an episode of fungemia was defined at the first isolation from a 
blood culture of a yeast strain from a patient with related signs and symptoms. 
Nosocomial fungemia was defined whenever the yeast isolate was obtained more than 
48h after hospital admission. Patients were grouped into five age categories: less than 
19 years, 19-40 years, 41-60 years, 61-70 years and more than 70 years old. For each 
individual patient, the outcome of the fungemia episode was evaluated at 30 days after 
the first yeast isolation. Death associated with fungemia was defined as death within 30 
days after recovery of the first yeast isolate, without any other concomitant cause of 
death, like intra-cerebral or gastrointestinal bleeding or pulmonary embolism.  
 
Identification and in vitro antifungal susceptibility testing of yeast isolates Yeasts 
were identified using Vitek 2 YST cards from bioMérieux (Marcy l’Etoile, France). The 
characterization of Candida glabrata sensu stricto, Candida bracarensis and Candida 
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nivariensis was confirmed as previously described by Romeo et al [138]. Candida 
parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis isolates 
were identified as previously described by Tavanti et al [139]. Furthermore, the 
identities of these species were confirmed by deoxyribonucleotide acid (DNA) 
amplification and further sequencing of ITS1 and ITS4 regions of ribosomal ribonucleic 
acid (RNA) operons. MIC was considered as the lowest concentration showing a 50% 
reduction on growth compared with control after 24h incubation for azoles and 
echinocandins. For AMB and 5FC the MIC was the lowest concentration showing a 
complete absence of growth compared to the control and 50% reduction of growth 
compared to the control, respectively – both after 48h incubation. MICs were 
determined for Fluconazole (FLC), Voriconazole (VOR), Posaconazole (POS), 
Anidulafungin (AND), Caspofungin (CAS), Micafungin (MCF), Amphotericin B 
(AMB) and 5-Flucytosine (5FC) by broth microdilution, regarding two different 
protocols: CLSI M27-A3 (S4) and EUCAST EDef 7.2 document [49, 50, 136]. Also, 
being aware of the inter-laboratory variation of CAS MIC values [57] we tried to 
minimize it by using a single drug powder lot and stock solution solvent. In order to 
compare both protocols we assigned Categorical Agreement (CA), expressing the level 
of discrepancy on the number of resistant isolates when categorized by one protocol or 
another. Reference powders for each antifungal agent were obtained from their 
respective manufacturers. FLC, CAS and MCF were dissolved in water and the other 
drugs in DMSO. Antifungal resistance rates were calculated regarding both protocols 
although for CLSI, several times, the Epidemiological Cutoff Values (ECV) were used; 
for EUCAST many breakpoints are still undefined.  For AMB, yeasts inhibited by ≤1 
mg/L were considered to be susceptible according to suggestions by Pfaller et al [140]. 
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The quality control (QC) strains C. parapsilosis ATCC 22019 and C. krusei ATCC 
6258 were included in all assays [49, 50, 136]. 
Statistical analysis A descriptive revision of the collected data was performed using 
Statistical Package for Social Sciences (SPSS) v21.0 (SPSS Software, Chicago, USA). 
Chi-squared tests were used to compare proportions and analyze differences in the 
species distribution and in antifungal susceptibility profiles. A P value below 0.05 was 
considered significant. 
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RESULTS 
 
Patient’s data A total of 240 fungemia episodes were reported in the current survey 
(corresponding to 240 different patients) and included in the study. The mean incidence 
of fungemia was 0.88 per 1000 admissions, ranging from 0.15 to 2.4 depending on the 
hospital. The mean incidence of nosocomial fungemia was 0.74 per 1000 admissions, 
ranging from 0.14 to 2.1. This corresponds to approximately 86% of all episodes of 
fungemia. In Portugal, Pediatrics admits neonates and children aged 18 years or under. 
However, often, these patients – especially adolescence - are admitted by other 
departments due to numerous and unspecified issues (Table 1). Fifty-seven per cent of 
the patients with fungemia were males and the most affected group was the one aged 
41-60 years (32%), closely followed by the group of patients over 70, together 
accounting for 62% of cases (Table 1). Most patients enrolled in this study were 
admitted at Intensive Care Unit (ICU) (39%) and surgical wards (30%). The mortality 
rate due to fungemia was 25%. The deadliest species was C. glabrata, with more than 
50% of patients dying within 30 days of fungemia detection (Table 1). 
 
Species distribution and identification Table 1 shows the most important 
characteristics regarding the top five recovered species, the total of the others species 
and an overall perspective. Fifteen different yeast species were identified and nearly 
60% of fungemias were caused by non-albicans species. The five most prevalent were 
C. albicans (40.4%), C. parapsilosis (22.9%), C. glabrata (13.3%), C. tropicalis (6.3%) 
and C. krusei (5%). Cryptococcus neoformans was responsible for eight (3.3%) 
episodes of fungemia followed by C. lusitaniae (2.5%), Candida guilliermondii (1.7%), 
Candida dubliniensis (1.3%) and Candida famata (1.3%). Single cases due to Candida 
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sake, Candida inconspicua, Candida haemulonii, Candida kefyr and Trichosporon 
mucoides were also found, as a whole accounting for 1.7% of all cases. Regarding the 
molecular identification of the cryptic species, from 55 isolates of C. parapsilosis sensu 
lato, 49 corresponded to C. parapsilosis sensu stricto, 4 to C. orthopsilosis (3 isolated 
from Medicine Department and 1 from ICU) and 2 to C. metapsilosis (both from the 
Medicine Department). The 32 isolates primarily identified as belonging to the C. 
glabrata group all corresponded to C. glabrata sensu stricto. Two cases of fungemia in 
neonates were observed, one infection caused by C. parapsilosis and another one by C. 
glabrata. We report three cases of fungemia in children under two years old, all caused 
by C. albicans. Very distinct geographic areas were covered by these hospitals, 
although no significant differences in species distribution were found. C. glabrata 
appears in more than half of the cases in ICU and Medicine Departments while C. 
tropicalis was mostly found in Surgery wards. 
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Table 1. Distribution and characteristics of the isolated yeasts. 
 
 
No. of isolates (%) 
 
C. albicans C. parapsilosis C. glabrata C. tropicalis C. krusei Other species Overall 
Gender 
Male 59 (61) 26 (47) 21 (66) 11 (73) 4 (33) 16 (55) 137 (57) 
Female 38 (39) 29 (53) 11 (34) 4 (27) 8 (67) 13 (45) 103 (43) 
Total 97 (40) 55 (23) 32 (13) 15 (6) 12 (5) 29 (12) 240 (100) 
Age group (years) 
<15 4 (4) 5 (9) - - - 2 (7) 11 (3) 
15-19 4 (4) 8 (15) 1 (3) - - 10 (35) 23 (10) 
20-40 10 (10) 4(7) 3(9) 2(13) 2(17) 6 (21) 27 (11) 
41-60 35 (35) 13(24) 9(29) 7(47) 6(50) 7 (24) 77 (32) 
61-70 15 (16) 7(13) 3(9) 3(20) 1(8) 2 (7) 31 (13) 
>70 29 (30) 18(32) 16(50) 3(20) 3(25) 2 (10) 71 (30) 
Hospital Department 
ICU 42(43) 21(38) 12 (38) 4(27) 5(42) 10 (35) 94(39) 
Surgery 22 (23) 18(33) 8(25) 8(53) 3(25) 11 (38) 70(30) 
Medicine 28 (29) 13(24) 11(34) 3(20) 4(33) 6 (21) 65(27) 
Pediatrics 5 (5) 3 (6) 1(3) - - 2 (7) 11 (5) 
Outcome 
Death 30 days 23 (24) 12 (22) 17 (53) 3 (20) - 4 (14) 59 (25)  
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Species susceptibility profiles Table 2 details all the data for susceptibility testing 
using CLSI and EUCAST protocols. Readings were made after 24h of incubation for 
azoles and echinocandins. For AMB and 5FC 48h readings were registered. Similar 
MIC results were obtained despite differences arising from both protocols (one dilution 
discrepancy above or below for each protocol was not been taken into account). 
Generally, CLSI breakpoints categorized less isolates as resistant (R) than EUCAST. 
Among the group of azoles, the highest percentage of resistance (9%) coupled C. 
glabrata to FLC, according to both protocols. Concerning the echinocandins, several 
differences were observed with the application of specific breakpoints for each protocol. 
Resistance to AMB and 5FC was rare. Regarding simultaneous resistance to antifungals 
of different classes, applying both protocols and excluding strains with intrinsic 
resistances such as C. krusei for FLC and C. neoformans for the echinocandins, we 
detected one isolate of T. mucoides (resistant to FLC, AND, CAS and MCF), one of C. 
krusei (resistant to AMB and CAS) and one of C. parapsilosis (resistant to FLC and 
CAS) (data not shown). Resistance to drugs within the same class was more frequent, 
with 8 strains of C. albicans and 1 of C. tropicalis showing resistance to the three azoles 
and 6 strains of C. parapsilosis being resistant to the three echinocandins. With the 
exception of three isolates (one each of C. glabrata, C. krusei and C. kefyr), which 
corresponded to a high MIC value (2 mg/L), all the other strains were susceptible to 
AMB with low MIC values, ranging from 0.03 to 0.125 mg/L. The 4 C. orthopsilosis 
and the 2 C. metapsilosis strains were found to be susceptible to all antifungals tested. 
Regarding the CA, half of the possible comparisons between CLSI and EUCAST had a 
CA of 100% while the other half was ranging from 42% - the lowest CA obtained 
confronting both protocols – in the case of C. krusei isolates to 5FC - to 97% in the case 
of C. albicans to VOR (see table 2).  
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Table 2. Distribution of minimum inhibitory concentration (MIC) values comparing the Clinical Laboratory Standards Institute (CLSI) and 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) protocols. 
 
Species (no.isolates) Drug 
R breakpoint or ECV No. of isolates with MIC (mg/L) No (%) of R 
CA (%) 
CLSI EUCAST 0,016 0,03 0,06 0,125 0,25 0,5 1 2 4 8 16 32 64 128 CLSI EUCAST 
C. albicans (97) 
AND >0.5 >0.03 88 2 3 
   
1 2 
 
1 - - - - 4 (4) 8 (8) 96 
CAS >0.5 a 
 
75 1 1 5 10 3 
  
2 - - - - 5 (5) - - 
MCF >0.5 >0.016 82 1 3 2 3 3 1 1 
 
1 - - - - 3 (3) 15 (15) 88 
FLC >4 >4 - - - 27 53 6 7 1 1 1 
  
1 
 
2 (2) 2 (2) 100 
VOR >0.5 >0.125 - 75 7 11 1 2 
    
1 - - - 1(1) 4 (4) 97 
POS >0.06* >0.06 - 81 5 5 5 
     
1 - - - 11(11) 11 (11) 100 
AMB >1 >1 11 21 54 1 2 4 4 
   
- - - - 0 0 100 
5FC >0.5* > 0.5 - - - 61 18 10 5 2 
    
1 - 8 (8) - - 
C. parapsilosis (55) 
AND >4 >4 17 
  
1 1 4 1 6 25 
  
- - - 0 0 100 
CAS >4 a 20 1 2 1 1 3 12 
 
3 10 2 - - - 12 (22) - - 
MCF >4 >2 16 4 
 
8 2 4 9 3 9 
   
- - 0 9 (16) 84 
FLC >4 >4 - - - 10 16 17 4 2 4 2 
    
2 (4) 2 (4) 100 
VOR >0.5 >0.125 
 
17 
 
23 8 7 
     
- - - 0 13 (24) 76 
POS >0.25* >0.06 
 
11 20 12 3 9 
     
- - - 9 (16) 24 (44) 73 
AMB >1 >1 
 
42 8 4 1 
      
- - - 0 0 100 
5FC >0.5* >0.5 - - - 49 3 2 1 
       
1 (2) - - 
C. glabrata (32) 
AND >0.25 >0.06 
 
19 7 3 2 1 
    
- - - - 1 (3) 6 (19) 84 
CAS >0.25 a 
 
8 6 3 4 10 1 
   
- - - - 11 (34) - - 
MCF >0.12 >0.03 6 21 
 
5 
      
- - - - 0 5 (16) 84 
FLC >32 >32 - - - 
  
2 1 8 7 11 
  
3 
 
3 (9) 3 (9) 100 
VOR >0.5* IE 
 
5 10 3 9 3 1 1 
   
- - - 2 (6) - - 
POS >2* IE 
 
4 4 7 5 3 9 
    
- - - 0 - - 
AMB >1 >1 
 
4 9 7 6 3 2 1 
      
1 (3) 1 (3) 100 
5FC >0.5* >0.5 - - - 22 2 5 3 
       
3 (9.4) - - 
C.tropicalis (15) 
AND >0.5 >0.06 
 
7 3 4 1 
     
- - - - 0 5 (33) 67 
CAS >0.5 a 
 
5 
 
2 4 3 1 
   
- - - - 1 (7) - - 
MCF >0.5 IE 
 
3 
 
5 3 4 
    
- - - - 0 - - 
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FLC >4 >4 - - - 5 3 3 
  
4 
     
0 0 100 
VOR >0.5 >0.125 
 
1 3 1 5 3 1 1 
   
- - - 2 (13) 10 (67) 47 
POS >0.12* >0.06 
 
2 1 3 4 2 3 
    
- - - 9 (60) 12 (80) 80 
AMB >1 >1 
 
12 3 
           
0 0 100 
5FC >0.5* >0.5 
   
6 4 4 
   
1 
    
1 (7) - - 
C. krusei (12) 
 
AND >0.5 >0.06 
 
8 
 
2 2 
     
- - - - 0 4 (33) 67 
CAS >0.5 a 
   
3 2 2 3 1 1 
 
- - - - 5 (42) - - 
MCF >0.5 IE 
   
3 6 3 
    
- - - - 0 - - 
FLC >64* b 
          
2 7 3 
 
- - - 
VOR >1 IE 
 
6 5 1 
       
- - - 0 - - 
POS >0.5* IE 
 
3 1 1 7 
      
- - - 0 - - 
AMB >1 >1 
 
9 1 
 
1 
  
1 
      
1 (8) 1 (8) 100 
5FC >32* >8 
        
2 3 6 1 
  
0 7 (58) 42 
Other spp.(20) 
AND >2 IE 2 3 1 7 1 1 3 1 1      1 (3) - - 
CAS >2 IE 4 1 3 2 1 5 1 2 1      1 (3) - - 
MCF >2 IE 2 1 3 2 3 2  4 2 1     3 (10) - - 
FLC >64 >4   1 4 3 4 3  1  3  1  1 (3) 4 (14) 90 
VOR >4 IE  10 2 3 4 1         0 - - 
POS >4 IE  10 3 3 2 1   1   -   0 - - 
AMB >1 IE  4 2 1 7 4 1 1       1 (3) - - 
5FC >32 IE 
  
3 6 3 6 1 2 
   
1 
  
1 (3) - - 
Overall (231) 
AND NA NA 107 39 14 13 7 6 5 9 26 1     6 (3) 23 (10) 93 
CAS NA NA 24 90 12 12 17 33 21 3 5 12 2    35 (15) - - 
MCF NA NA 106 30 6 25 17 16 10 8 11 2     6 (3) 29 (13) 90 
FLC NA NA   1 46 75 32 15 11 17 14 5 7 8  8 (4) 11 (5) 99 
VOR NA NA  114 27 42 27 16 13 2   1    3 (1) 27 (12) 89 
POS NA NA  111 34 31 26 15 12  1 1     29 (13) 47 (20) 93 
AMB NA NA 11 92 77 13 17 11 7 3       3 (1) 2 (1) 100 
5FC NA NA   3 144 30 27 10 4 2 4 6 2 1  14 (6) 7 (3) 97 
ECV – Epidemiological Cutoff Value; IE – Insufficient Evidence; NA – not applicable. 
a Due to significant interlaboratory variation in MIC ranges for caspofungin, EUCAST breakpoints have not yet been established. 
b Isolates of Candida krusei are assumed to be intrinsically resistant to fluconazole (FLC). 
c Except Cryptococcus neoformans and Trichosporon mucoides. 
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DISCUSSION  
Our study reports a mean incidence of fungemia of 0.88/1000 admissions 
(ranging from 0.15 to 2.4), which is comparable to recent data from other European 
countries [141, 142], but being somewhat lower than in Brazil [143]. A previous study 
in Portugal, based on a single university hospital, found a higher incidence of 2.7/1000 
admissions [144]. Healthcare-associated fungemia remains the vast majority, 
representing more than 80% in most studies [43, 145]. Thus, it is not surprising that 
most of the isolates were recovered from ICU, surgery and internal medicine 
departments, since most of the patients admitted to these wards are in poor health 
conditions and are submitted to invasive procedures and aggressive antibiotic and 
immunosuppressive drug regimens, which both are associated with increased rates of 
fungal infections [39, 146]. We report a 30-day mortality rate of 25%, with more than 
half (53%) of C. glabrata fungemias being lethal. Costa-de-Oliveira et al. reported five 
years ago even higher values, with a 78% mortality rate for C. glabrata fungemia and 
46%, 30% and 53% for C. albicans, C. parapsilosis and C. tropicalis, respectively 
[144]. On the reasons behind this decrease one can only speculated. In other European 
studies, rates of fungemia ranged from around 30% [43, 141] to 40% [37, 145], but C. 
glabrata did not carry such a death burden.  
C. albicans appears as the leading causative agent of fungemia in our study 
(40%), as reported in other European studies [9, 37, 43, 141, 147]. However, the second 
position is not occupied by C. parapsilosis in most European countries; instead, C. 
glabrata appears repeatedly as the most common non-albicans species isolated from 
blood cultures [134], reaching almost a third [9, 145]. The causes of the difference in 
incidence are unknown but, curiously, our data parallel those of Spanish and Brazilian 
studies, where C. parapsilosis is responsible for 27% and 37% of cases of fungemia 
Species distribution and in vitro antifungal susceptibility profiles of yeast isolates from 
invasive infections during a Portuguese multicentre survey 
 
43 
 
[142, 148]. C. orthopsilosis and C. metapsilosis represented 7.3 and 3.6%, respectively, 
of the C. parapsilosis sensu lato isolates, while C. nivariensis and C. bracarensis were 
not identified, coinciding with results obtained in other Mediterranean countries [142, 
149, 150] and Brazil [148].  
Concerning our susceptibility results, comparing CLSI and EUCAST protocols 
implies limitations because several breakpoints are undefined and some are discordant, 
with EUCAST being predisposed to lower breakpoint values. However, in recent years, 
great efforts have been made to overcome those differences and to harmonize both 
protocols [137, 151, 152]. The similar MIC values obtained by both protocols, despite 
the differences on practical detail and test execution, are in agreement with those 
obtained by Pfaller and colleagues [151, 152]. This study represents another step 
towards a unified categorization of resistant isolates, strengthened by the concordant 
results. Overall, it is important to highlight the relative small size of our sample and 
point out that more isolates (either through greater participation or by extending the 
period of the study) would boost our results.  
This is the first multicenter study carried out in Portugal on this topic. These 
studies provide valuable data on the species distribution and antifungal susceptibility. 
This information is important since it can guide clinicians in the treatment of fungal 
infections and, ultimately, reduce the mortality due to fungemia, which still remains at 
unacceptably high values. 
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ABSTRACT 
Acquisition of azole resistance by clinically relevant yeasts in nature may result 
in a significant, yet undetermined, impact in human health. The main goal of this study 
was to assess the development of cross-resistance between agricultural and clinical 
azoles by Candida spp. An in vitro induction assay was performed, for a period of 90 
days, with Prochloraz (PCZ) – an agricultural antifungal. Afterwards, the induced 
molecular resistance mechanisms were unveiled. 
MIC value of PCZ increased significantly in all Candida spp. isolates. However, 
only C. glabrata developed cross-resistance to fluconazole and posaconazole. The 
increased MIC values were stable. C. glabrata azole resistance acquisition triggered by 
PCZ exposure involved the upregulation of the ATP binding Cassette multidrug 
transporter genes and the transcription factor, PDR1. Single mutation previously 
implicated in azole resistance was found in PDR1 while ERG11 showed several 
synonymous single nucleotide polymorphisms. 
These results might explain why C. glabrata is so commonly less susceptible to 
clinical azoles, suggesting that its exposure to agricultural azole antifungals may be 
associated to the emergence of cross-resistance. Such studies forward potential 
explanations for the worldwide increasing clinical prevalence of C. glabrata and the 
associated worse prognosis of an infection by this species. 
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INTRODUCTION  
Although Candida albicans is still the most frequently isolated Candida 
organisms, C. glabrata and C. parapsilosis have recently emerged as the second or third 
most common agent of invasive candidosis [34, 141, 144]. In an attend to understand 
the growing clinical relevance of Candida species, several facts were considered, 
namely: the fact that antifungal agents used for crop protection of the azole class, (e.g. 
propiconazole, prochloraz, imazalil), very similar to those used in human therapy, are 
extensively used in agriculture within the EU [87]; Candida organisms are human 
commensals, colonizing places like the skin or the gastro-intestinal tract, but they are 
also ubiquitous in the environment [153]. Such long antimicrobial pressure is 
recognized to lead to drug resistance. Fungal diseases are problematic for both human 
health and agriculture, azole drugs representing the core therapy for both; such 
circumstance may represent an initial step in the emergence of clinical resistant fungal 
isolates. Therefore, antifungal resistance may perhaps be driven by the extensive use of 
azole fungicides in agriculture, similar to azoles used in humans. Resistance of yeast 
clinical isolates to azole antifungal agents can result from either overexpression or 
mutations in ERG11 gene. Alternatively, the cells can fail to accumulate azole 
antifungal agents due to enhanced drug efflux, a consequence of transcriptional 
activation of drug efflux pumps. At least two families of multidrug transporters, the 
ABC transporter family and the MFS, are involved in azole resistance [63] . Therefore, 
the purpose of this study was to evaluate the potential development of cross-resistance 
by the extensive use of azole fungicides in agriculture, similar to azoles used in humans.  
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MATERIALS AND METHODS 
 
Strains One clinical isolate each of Candida albicans, C. parapsilosis and C. glabrata 
were selected from the fungal collection of the Microbiology Department of Faculty of 
Medicine, University of Porto. They were chosen according to the corresponding 
clinical information and susceptibility profile to clinical azoles, i.e., strains should have 
been isolated from patients without previous exposure to any clinical azole and be 
categorized as susceptible to them. Strains were kept in a YPD medium (0.3% yeast 
extract, 1% peptone and 2% dextrose) broth supplemented with 10% glycerol, stored at 
-80ºC; after thawing, strains were subcultured twice and incubate at 35ºC, for 48 hours 
on Sabouraud dextrose agar (Difco) to assess the purity of culture. 
 
Antifingal agents PCZ was used as a representative of agriculture azoles; Fluconazole 
(FLC), Voriconazole (VCZ) and Posaconazole (POS) as clinical azoles. Anidulafungin 
(AND) was included as representative of another class of antifungals – echinocandins. 
PCZ was ressuspended in 80% acetone solution at a final concentration of 5 mg/L. 
Clinical azoles were dissolved in dimethysulphoxide (DMSO) to obtain a stock solution 
of 10 mg/L. All drugs were stored at -20ºC until use.  
 
Antifungal susceptibility testing Broth microdilution susceptibility assay was 
performed in order to evaluate the initial minimal inhibitory concentrations (MIC) of 
the isolates to PCZ and to confirm results for all the clinical azoles, according to the 
Clinical and Laboratory Standards Institute M27-A3 protocol (applying species-specific 
breakpoints, as advised in supplement S4) [50]. Drug concentration ranged from 0.125 
to 64 mg/L of FLC and PCZ; from 0.0313 to 16 mg/L of POS, VCZ and AND; MIC 
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determination was repeated at least twice. C. albicans and C. parapsilosis strains for 
which FLC MIC was ≤2mg/L were categorized as susceptible and resistant at MIC >4 
mg/L. C. glabrata was considered FLC susceptible-dose dependent (S-DD) at MIC ≤32 
mg/L and resistant at MIC >32 mg/L. VRC MIC ≤0.125 mg/L for C. albicans and C. 
parapsilosis was considered as susceptible and ≥1 mg/L as a resistant phenotype. Since 
no specific breakpoints are available for C. glabrata regarding VRC or for any of the 
three species to POS, we used the older breakpoints for both antifungals: susceptible, 
MIC ≤ 1 mg/L; intermediate, MIC = 2 mg/L; resistant MIC ≥ 4 mg/L. For AND, the 
three different species have three different breakpoints: C. albicans was classified as 
susceptible whenever MIC ≤0.25 mg/L and resistant whenever MIC >0.5 mg/L; C. 
parapsilosis was susceptible or resistant according to a MIC value ≤2 mg/L or >4 mg/L, 
respectively; C. glabrata was categorized as susceptible whenever AND MIC ≤0.12 
mg/L and as resistant if >0.25 mg/L.  
 
In vitro induction assays A single, randomly selected colony from each strain was 
incubated in 10 mL of YPD medium overnight in a shaker at 180 rpm, 35 ºC. Aliquots 
of this culture, containing 106 blastoconidia, were transferred to different vials, each one 
containing 10 mL of same culture medium with MIC of PCZ for each strain (0.25 μl, 1 
μl and 0.5 μl of PCZ for C. albicans, C. parapsilosis and C. glabrata, respectively) and 
incubated overnight as described above [154, 155]. The following day, aliquots from 
each culture containing 106 blastoconidia were again transferred into fresh medium 
containing the same antifungal concentration and reincubated as described. Each day, 
during a 90 days period, a 0.75 mL aliquot from each subculture was mixed with 0.75 
mL of 80% glycerol and frozen at -70ºC for later testing. The induction assay was 
carried out for 90 days keeping daily constant the concentration of PCZ, corresponding 
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to the minimal inhibitory concentration (MIC) value for each species. MIC of PCZ was 
determined every ten days along the 90 days of assay. Whenever a marked MIC 
increase was observed (four fold the initial PCZ MIC), the MIC values of clinical 
antifungals were determined as well.  
 
Stability of in vitro developed resistance phenotype In order to assess the stability of 
the developed MIC increment to PCZ and of the developed cross-resistance to clinical 
azoles, the induced strains were afterwards sub-cultured for an additional ninety days in 
the absence of antifungals and MIC values re-determined, as previously described in the 
induction assay. 
 
RNA isolation RNA was extracted from a 50 ml volume of a C. glabrata culture that 
had been grown overnight in YPD broth (without antifungal drugs) at 150 rpm and 
35°C to an optical density of approximately 1.0 at 600 nm. Total RNA was extracted 
using the hot acid phenol method, as described by Köhrer & Domdey [156]. RNA 
concentration was assessed by Nanodrop ND-1000 and the RNA quality and integrity 
levels were controlled by capillary electrophoresis in the Agilent 2100 Bioanalyzer 
(Agilent Technologies, Palo Alto, CA), according to the manufacturer’s instruction. 
Only samples yielding a 28S rRNA/18S rRNA ratio ranging from 1.6 to 2.2, and 
showing the absence of degradation were used for further testing. 
 
cDNA synthesis and RT-qPCR For each real-time quantitative PCR (RT-qPCR) 
analysis, three replicates for each species, of the initial and final strain, were included: 
analysis involved the search of the most important genes for each species, reported as 
responsible for azole resistance. for C. albicans CDR1, CDR2, MDR1 and ERG11; For 
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C. parapsilosis MRR1, MDR1, UPC2, NDT80, ERG6 and ERG11; and for C. glabrata 
PDR1, CDR1, PDH1, YOR1, SNQ2 and ERG11 [93]. The PCR protocol used included a 
first minute hot start at 95°C, followed by a 35-cycle program composed of a 15 
seconds denaturation step at 95°C, a 30 seconds annealing step at 60°C, and a 30 
seconds extension step at 60°C, followed by a 5-minutes final extension step at 60°C. 
PCRs were performed using PerfeCTa SYBR green Fast Mix (Quanta Biosciences, 
Gaithersburg, MD, USA) in a Realplex Mastercycler instrument (Eppendorf, Madrid, 
Spain). The signal obtained for each gene was normalized with the ACT1 for C. 
albicans and C. glabrata; and with TUB4 for C. parapsilosis. 
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RESULTS 
 
In vitro induction assay In vitro induction assays were performed with three isolates of 
each species with similar results within the same species – one isolate representative of 
each species was shown in the results. The three species developed a progressive 
increment of PCZ MIC value comparatively to the initially determined value. As no 
breakpoints exist for PCZ, we abstained from using the terms “susceptible” or 
“resistant”. After ten days of induction, all Candida species developed a higher MIC 
value to PCZ; this increase was 32 times in C. albicans and C. parapsilosis and 64 
times in C. glabrata. In addition, a concomitant increase of the MIC of FLC, VCZ and 
POS was observed, but only for C. glabrata. VCZ was the less affected clinical azole. 
Cross-resistance in C. glabrata was well established after sixty days of induction with 
PCZ, for FLC and POS. No cross-resistance was registered regarding AND, for any 
species (Table 1).  
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Table 1. Susceptibility profile of Candida species tested to PCZ, triazoles and 
anidulafungin. 
 
 
 
 
 
 
 
 
Species 
Time of 
exposure 
to PCZ 
(days) 
MIC (mg/L) 
PCZ FLC VRC POS AND 
C. albicans 
0 0.5 0.25 0.03 0.03 0.015 
10     16 0.25 0.06 0.5 0.03 
30     16 0.5 0.06 0.5 0.03 
60     16 0.5 0.06 0.5 0.03 
90 16 1 0.06 0.5 0.03 
 90 16 0.5 0.06 0.5 0.03 
C. parapsilosis 
0 2 0.5 0.03 0.03 1 
10 64 1 0.06 1 1 
30 64 1 0.06 1 1 
60 64 1 0.06 2 2 
90 64 1 0.06 2 2 
 90 64 1 0.06 2 2 
C. glabrata 
0 1 1 0.25 0.03 0.06 
10 64 16 0.5 16 0.125 
30 64 16 0.5 16 0.125 
60 64 32-64 1 16 0.125 
90 64 32 1 16 0.125 
 90 64 2 0.25 16 0.125 
PCZ=Prochloraz; FLC=Fluconazole; VCZ=Voriconazole; 
POS=Posaconazole; AND=Anidulafungin;  
= MIC after 90 days of culture in the absence of PCZ. 
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Stability of the in vitro developed resistant phenotype The in vitro developed high 
MIC values of PCZ maintained stable following removal of the selective pressure of the 
drug, for all species. Also, the cross-resistance observed in C. glabrata did not revert in 
the absence of the inducer antifungal, PCZ.  
 
Gene Expression Profile No significant difference was obtained between the initial and 
final strain, regarding gene expression in C. albicans or C. parapsilosis. C. glabrata 
was the only species that consistently overexpressed genes previously associated with 
azole resistance due to upregulation of efflux pumps [157]. Meanwhile, ERG11 was 
found to be dowregulated (0.141 fold and p=0.775). PCZ exposure triggered 
overexpression of ATP Binding Cassette (ABC) multidrug transporters PDH1, YOR1, 
CDR1 and SNQ2. The first two genes were found to be 48.5 (p<0.001) and 66.8 
(p<0.001) fold overexpressed, respectively; CDR1 and SNQ2 showed an expression 
level of 2.9 (p=0.008) and 1.3 (p=0.193) fold respectively. These multidrug transporters 
are regulated by PDR1 encoded transcription factor, which was also found to be 
overexpressed – 6.8 fold (p<0.001) (Figure 1). Therefore, both C. glabrata 
transcriptional factor and related efflux genes were upregulated following the in vitro 
induction assay.  To determine whether resistance was associated with mutations: ERG 
11 and PDR1 genes were sequenced for a single C. glabrata isolate. DNA products 
were sequenced in an ABI Prism 3130 genetic analyzer (Applied Biosystems). A 
G727A point mutation in PDR1 gene was found, leading to an aspartic acid to 
asparagine amino acid substitution at codon 243. ERG11 analysis revealed several 
synonymous single nucleotide polymorphims (SNPs) (Figure 2).  
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Figure 1.  Gene expression alterations triggered by PCZ exposure in C. glabrata. 
Black bars represent the susceptible initial strain – day 0; gray bars represent the same 
strain after the induction assay, day 90.  Comparative gene expression profile between 
the initial, day 0, susceptible strain and the strain after the induction assay, day 90. Gene 
expression is expressed as average with standard deviation of three independent 
experiments. Each mean value was normalized with the ACT1 gene. 
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Figure 2. Single Nucleotide Polymorphisms (SNPs) found in Candida glabrata PDR1 
and ERG11 genes. (A) PDR1 missense mutation G727A results in the amino acid 
change D243N. (B) Several synonymous SNPs throughout the ERG11 gene. 
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DISCUSSION 
In recent years the concept that the use of azoles in agriculture would not only 
influence plant pathogenic species but would also inevitably impair susceptible species 
of opportunistic human pathogens has gained relevance, especially in the case of 
filamentous fungi like Aspergillus fumigatus; such drugs may also leave an impact in 
saprophytic human flora [113, 125, 158, 159]. In fact, such an imbalance might affect 
the endogenous population of other medically important pathogens like yeasts, such as 
Candida species. It is generally accepted that a persistent antimicrobial pressure on a 
complex microbial population will lead to selection of resistant clones, particularly if 
the antimicrobial effect is not microbiocidal. Systemic infections due to Candida 
glabrata are characterized by a high mortality rate; they are difficult to treat due to the 
intrinsically low susceptibility of this species to azole drugs, especially to fluconazole 
[160] . In addition, C. glabrata easily develops fluconazole resistance in response to 
drug exposure during patient treatment. In fact, it is now common to find azole-resistant 
Candida isolates from patients not previously exposed to clinical antifungal agents 
[161, 162]. In our study, in all the three species PCZ MIC value increased from 32 to 64 
fold compared to the initial value. However, neither C. albicans nor C. parapsilosis 
developed cross-resistance. Anidulafungin activity was not impaired following the 
selective pressure of an agricultural azole compound, which is not surprising 
considering that echinocandins have a different mechanism of action. Our results 
suggest a different perspective on the way C. glabrata species develop stable resistance 
to medical triazoles. Drug efflux, resulting from the increased expression of ABC 
transporter proteins is the predominant mechanism by which C. glabrata mediates 
resistance to a wide range of antifungal compounds. Also Pdr1, as the principal 
regulator of ABC transporter gene expression, has been found to be a key player in such 
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resistance [63, 157, 163, 164]. These genetic alterations may transform an intrinsically 
susceptible to a permanently resistant phenotype. In fact, haploid fungal cells - as is the 
case of C. glabrata - might be more prone to such events [165]. We assessed the most 
common associated genes with azole resistance and found that all ABC transporters 
were upregulated, as well as their regulatory transcription factor. To our knowledge, this 
is the first time that YOR1 was found to have such high expression in a C. glabrata 
azole resistant strain – it was 66.8 fold overexpressed. Also, previous reports addressing 
genes involved in azole resistance in C. glabrata state that the predominant basis for 
acquired azole resistance is the constitutively upregulated expression of multidrug 
transporter genes CDR1 and PDH1 [63, 157, 166]. Borst and colleagues reported a 
rapid and stable acquisition of azole resistance by C. glabrata after an induction assay 
with FLC; the same ABC transporters were found overexpressed while no contribution 
of ERG11 was verified [154]. As previously described, a single point mutation was 
found at PDR1 while ERG11 only showed the existence of several synonymous SNPs 
suggesting that this gene was not involved in C. glabrata azole resistance in the isolate 
examined [63, 166]. Certainly, additional studies are necessary to address the 
involvement of such genes in the development of azole cross-resistance triggered by the 
selective pressure of an agricultural drug.  
In conclusion, apart from very few speculative reports published some years ago, 
there is still no evidence for a clear correlation between the agricultural use of azoles 
and the increasing clinical azole resistance [42, 116, 167]. Nevertheless, our results 
strongly suggest such possibility and have the merit to put in evidence the molecular 
mechanisms triggered by such an exposure.  
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ABSTRACT 
The purpose of this study is to unveil whether azole antifungals used in 
agriculture, similar to the clinical azoles used in humans, can evoke resistance among 
relevant human pathogens like Aspergillus fumigatus, an ubiquitous agent in nature. 
Additionally, cross-resistance with clinical azoles was investigated. Antifungal 
susceptibility testing of environmental and clinical isolates of A. fumigatus was 
performed according to the CLSI M38-A2 protocol. In vitro induction assays were 
conducted involving daily incubation of susceptible A. fumigatus isolates, at 35ºC and 
180 rpm, in fresh GYEP broth medium supplemented with PCZ, a potent agricultural 
antifungal, for a period of 30 days. MIC of PCZ and clinical azoles were monitored 
every ten days. In order to assess the stability of the developed MIC, the strains were 
afterwards sub-cultured for an additional 3 0 days in the absence of antifungal. Along 
the in vitro induction process, microscopic and macroscopic cultural observations were 
registered.  
MIC of PCZ increased over 32 times in just ten days after initial PCZ exposure; 
cross-resistance to all tested clinical azoles was observed. The new MIC value of 
agricultural and of clinical azoles maintained stable in the absence of the selective PCZ 
pressure. PCZ exposure was also associated to morphological colony changes: 
macroscopically the colonies became mostly white, losing the typical pigmentation; 
microscopic examination revealed the absence of conidiation.  
PCZ exposure induced Aspergillus fumigatus morphological changes and an 
evident increase of MIC value to PCZ as well as the development of cross-resistance 
with posaconazole, itraconazole and voriconazole. 
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INTRODUCTION 
The ubiquitous saprophytic mould Aspergillus fumigatus is known to cause a 
spectrum of diseases in humans, including allergic syndromes, noninvasive infections, 
as well as invasive aspergillosis, a condition associated with significant morbidity and 
mortality [168]. A. fumigatus is one of the human pathogenic fungi that have a natural 
habitat in the environment, including soil and plants [169]. Some members of the azole 
drug class, which includes voriconazole and posaconazole have been shown to be 
effective in the treatment of invasive aspergillosis [170]. While azole resistance among 
clinical A. fumigatus isolates has for long been considered to be an uncommon finding, 
recently multiazole resistance has been reported to be emerging and is increasingly 
recognized as a cause of clinical treatment failure [171, 172]. In agriculture, thousands 
of tons of azoles are sold annually for the purpose of plant protection, either to control 
fungal growth that can cause extensive loss of crops or to prevent, or to ease the 
problem of postharvest spoilage of plants and fruits [87]. All azoles compounds mode 
of action - irrespectively of their chemical structure and variable biological properties - 
is based on the interference with the activity of fungal lanosterol 14 alpha-demethylase; 
such enzyme is responsible for the transformation of lanosterol in ergosterol, an 
essential component of the fungal cytoplasmatic membrane which is encoded by 
Cyp51A gene in A. fumigatus. The inhibition of ergosterol formation results in cell wall 
disorganization and, finally, the impairment of fungal growth. The mode of action of 
azoles is, therefore, fungistatic rather than fungicidal. It is well known that a strong and 
persistent antimicrobial pressure can lead to the selection of resistant clones within a 
microbial population, particularly if the drug effect is static rather than microbiocidal 
[159]. Since azoles are the mainstay treatment for both human and agricultural fungal 
diseases, a major concern is the predictable emergence of cross-resistance to clinical A. 
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fumigatus isolates that is already observed in several countries, driven by the massive 
use of azole fungicides in agriculture, which have the same mechanism of action as 
those used in humans [113, 125, 126, 158, 159]. The aim of our study was to investigate 
whether PCZ, a fungicide extensively use in agriculture, could be associated with the 
emergence of cross-resistance with clinical azoles among A. fumigatus.   
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MATERIALS AND METHODS 
 
Organisms Two clinical isolates of A. fumigatus, LMF05 and LMF11, and one 
environmental A. fumigatus isolate (LMN60, recovered from a garden nearby the 
hospital), were used in this study. The isolates were identified as belonging to A. 
fumigatus species by macroscopic and microscopic morphology, the ability to grow at 
48ºC and by using MALDI-TOF MS to accurately discriminate A. fumigatus from a 
new sibling species A. lentulus, which cannot be distinguished by morphological 
characteristics or growth peculiarities [173].  Long-term preservation of conidial 
suspensions of the isolates was made in a GYEP medium (2% glucose, 0.3% yeast 
extract, 1% peptone) broth supplemented with 10% glycerol and stored at -80◦C. 
Working cultures were subsequently maintained during 2 weeks on Sabouraud dextrose 
agar slants and plates at 4◦C.  
 
Antifungal agents and susceptibility profile Prochloraz (PCZ) is a non-systemic 
imidazole fungicide – an ergosterol biosynthesis inhibitor -  it was selected and used as 
a representative of agricultural azoles after a previous MIC screening where it showed  
to be the less active drug upon the selected strains, i.e., it had the lower MIC values 
which was a prerequisite for this induction experiment; Fluconazole (FLC), 
Voriconazole (VCZ), Posaconazole (POS) and Itraconazole (ITZ) as clinical azoles. 
Prochloraz was ressuspended in 80% acetone solution at a final concentration of 5 
mg/L. Clinical azoles were dissolved in dimethysulphoxide (DMSO) to obtain stock 
solutions of 10 mg/L. All drugs were stored at -20ºC. Broth microdilution susceptibility 
assay was performed according to the Clinical and Laboratory Standards Institute M38-
A2 protocol in order to evaluate the initial minimal inhibitory concentrations (MIC) of 
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PCZ and of all the clinical azoles [51]. Drug concentration ranged from 0.125 to 64 
mg/L of FLC and PCZ; and 0.0313 to 16 mg/L of POS, VCZ and ITZ. A. fumigatus 
ATCC 46645 was included for quality control of susceptibility testing. Also, FLC was 
used as control, since A. fumigatus shows a non-susceptible phenotype and MIC is most 
often above 64 mg/L for this species. MIC of azoles was defined as the lowest 
concentration of the drug that produced no visible growth following 48 hours of 
incubation. MIC determination was repeated at least twice.  
 
In vitro induction experiments Induction experiments were performed with the 
agricultural azole PCZ. A. fumigatus isolates were grown on Saboraud dextrose agar at 
37ºC for 72h; conidia were harvested by flooding the surface of the slants with 
phosphate-buffered saline (PBS) containing 0.025% (vol/vol) tween 80 while gently 
rocking. The conidial suspensions were then adjusted using specific spectrophotometric 
readings at 550 nm to a final concentration of 5x104 conidia per militer [174]; one 
militer of each distinct isolate suspension was transferred to 9 ml of GYEP broth 
supplemented with sub-inhibitory concentrations of PCZ (0.06 mg/L for both LMF05 
and LMF11; 0.125 mg/L for LMN60) and incubated overnight at 37ºC with agitation 
(180rpm). Daily, after vigorous vortexing for 60 seconds, one militer from each culture 
was transferred to fresh GYEP medium supplemented with PCZ and in parallel, 1 ml of 
culture was added with 10% glycerol and frozen at -80ºC. This procedure was repeated 
along thirty consecutive days.  
 
Susceptibility testing/ Stability of in vitro developed resistance phenotype MICs of 
PCZ were determined every five days along the thirty days of induction assay. No 
official breakpoints are yet defined for PCZ; therefore, whenever a marked MIC 
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increase was observed (four fold the initial PCZ MIC), the MIC values of clinical 
antifungals were determined. In order to assess the stability of the developed MIC 
increment to PCZ and of the developed cross-resistance to clinical azoles, the induced 
strains were afterwards sub-cultured for an additional thirty days in the absence of the 
drug and MIC values re-determined, as previously described.  
 
Culture macro and micro morphology Along the induction process, every two days, a 
loopful was inoculated in Saboraud Agar slants to check for viability and purity of 
culture. Macro and microscopical growth characteristics were registered. Colony 
morphology and pigmentation were recorded photographically using a Reflex Nikon 
D3200 Camera and images were processed by Adobe Photo Deluxe Image Processing 
Program (San Jose, CA, USA). Microscopical images of hyphae changes from the 
original A. fumigatus strain and the resistant induced one were capture with a Zeiss-
Axioplan-2 microscope equipped with Axio Cam and by using the AxioVision 3.0 
digital imaging software. 
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RESULTS AND DISCUSSION 
The 3 isolates developed a progressive increment of PCZ MIC value 
comparatively to the initially determined value. In addition, a concomitant increase of 
the MIC of VCZ, POS and ITZ, was observed (Table 1). From day 0 of evaluation until 
day 30 during the induction assay, MIC of PCZ increased 256 times. Concerning the 
clinical azoles, cross-resistance was developed for all days; all isolates changed from a 
susceptible to a resistant phenotype, according to Meletiadis and colleagues [175].  
 
Table 1. Susceptibility pattern of tested A. fumigatus isolates to PCZ and clinical 
azoles. 
 
A. fumigatus 
isolate 
Time of 
exposure 
(days) 
MIC (mg/L) 
PCZ VRC POS ITZ FLC 
LMF05 
0 0.125 0.125 0.25 2 >64 
10 0.25 0.25 0.5 2 >64 
20 8 2 1 4 >64 
30 32 8 2 8 >64 
 30 32 2 2 2 >64 
LMF11 
0 0.125 0.25 0.125 0.5 >64 
10 0.125 2 0.25 1 >64 
20 8 8 1 2 >64 
30 32 >16 4 4 >64 
 30 32 2 1 0.5 >64 
LMN60 
0 0.25 0.25 0.125 0.25 >64 
10 4 8 0.25 1 >64 
20 8 8 0.5 2 >64 
30 64 >16 4 4 >64 
 30 64 2 1 0.25 >64 
PCZ= Prochloraz; VCZ= Voriconazole; POS= Posaconazole; ITZ= 
Itraconazole; FLU= Fluconazole; = MIC after 30 days of culture in the 
absence of PCZ. 
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In fact, there are several studies that have characterized azole resistance in A. fumigatus 
and most recently quite a few addressed the possible cross-resistance between 
environmental and medical azoles [113, 125, 126, 158]. Our study demonstrated the 
time frame between the introduction of a widely used agricultural fungicide and the 
emergence of cross-resistance to medical triazoles. The exposure of other clinical 
relevant moulds to agricultural azoles might therefore be associated with the emergence 
of cross-resistance to clinical antifungals. Besides the emergence of cross-resistance, we 
found that PCZ exposure caused marked morphological colony changes, both at 
macroscopical level (the colonies turned white losing the characteristic pigmentation) 
and microscopic examination revealed the progressive nonappearance of conidiation 
during the induction assay. Initially it was noticeable a macroscopic modification of the 
pigmentation of A. fumigatus colonies, changing from the original green colour to white 
(Figure 1 A, B and C). 
Figure 1. Photographs of Sabouraud dextrose agar plates showing macroscopic 
morphological changes of colonies of A. fumigatus following exposure to subinhibitory 
concentration of PCZ. A. Initial morphological aspect (control). B. After fifteen days. 
C. After thirty days. 
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Figure 2. Photomicrographs of A. fumigatus colonies using the cellotape flag technique 
preparation with lactophenol cotton blue staining. Microscopic morphological changes 
in the development of conidiation of A. fumigatus following exposure to subinhibitory 
concentration of PCZ. A. Initial morphological aspect (control). B. After fifteen days. 
C. After thirty days. 
 
With the increase of MIC values of PCZ, colonies of A. fumigatus became 
totally white (Figure1C) and also less and smaller. Microscopic examination of such 
macroscopic pigmentation change showed a progressive absence of conidiation. The 
original strain (Figure 1A) showed normal microscopic features regarding conidiation 
(Figure 2A) while almost white colonies (Figure 1B) showed almost complete absence 
of conidiation (Figure 2B), the totally white mycelia (Figure 1C) corresponded solely 
to hyphae and very little conidiophore structures but yet immature, ie, without any 
conidia (Figure 2C). Changes in the pigmentation of A. fumigatus colonies and the 
absence of conidia as consequence of azoles’ effect have already been reported. 
Varanasi and colleagues speculate that azoles may bind to a phytochrome-like 
regulatory molecule inhibiting the initiation and subsequent development of 
conidiophores in Aspergillus species and such mode of action could also explain the 
different levels of inhibition displayed by other tested azoles and why echinocandins 
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and polyenes did not shown this effect [176]. Notably, such morphological changes may 
be responsible for laboratorial diagnostic misidentification of the fungal genus/species, 
following its initial isolation, with the inherent consequences [177]. 
The in vitro developed high MIC values of PCZ maintained stable following 
removal of the selective pressure of the drug. For VRC, the MIC value decreased only 
after 30 days of incubation without the selective pressure, changing the susceptibility 
phenotype from resistant to intermediate. For POS, the developed MIC value also 
decreased but not enough to change the phenotype of resistance. Regarding ITZ, for 
both LMF11 and LMN60, it was observed the complete reversibility of the resistant 
phenotype in the absence of PCZ, ie, the MIC reverted to the initial value and that value 
is categorized as susceptible. However, strain LMF05 has, since day zero, ITZ MIC of 2 
mg/L which falls in resistant category. Following removal of the selective pressure of 
PCZ, conidiation reappeared together with the green typical colour of mature colonies, 
in all isolates. Since PCZ was responsible for the emergence of stable resistance to itself 
and to very important medical triazoles in A. fumigatus, a resistance mechanism may 
have been developed. Previous reports describe cyp51A mutation, efflux pump 
overexpression and/or target upregulation as the main mechanisms responsible for such 
resistance [28, 59, 111]. A clonal expansion of isolates harbouring the TR34/L98H 
mutation has been reported across several countries [28, 59, 111, 178]. 
Interestingly, besides the fact that these resistant isolates are less genetically 
variable than susceptible ones, no impact on fitness was observed [178]. The 
phenotypic results (Figures 1 and 2) and the stability of the developed resistance 
(Table 1) herein reported suggest the same. Future studies aiming to assess the 
underlying molecular resistance mechanisms, not only from these induced 
resistant strains but also from isolates with naturally high MIC values to PCZ and 
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resistant to medical azoles without previous in vitro induction, will certainly be 
our next step. Meanwhile, our study suggests that the abuse of azole antifungals in 
nature may cause serious human health problems since azole resistance and cross-
resistance has the potential to further compromise the efficacy of clinical azoles in 
the future [28, 167, 171, 178, 179]. Furthermore, we can speculate that the 
exposure of clinically relevant moulds other than A. fumigatus to agricultural 
azoles may also be associated with the emergence of cross-resistance to clinical 
azoles. Several compounds are being tested in order to find new antifungal alternatives, 
anticipating the possible loss of efficacy of clinical azoles [180]. On the other hand, 
efforts should be made to find safer compounds to use in agriculture. 
 
CONCLUSIONS 
In order to assess the real dimension of Aspergillus resistance, a susceptibility test 
should be performed in all isolates from patients with Aspergillus infection. Moreover, 
for patients with severe infection initial combination therapy may be considered in 
geographical areas with high prevalence of environmental azole resistant isolates. 
Ultimately, surveillance studies in both clinical and in environment settings should be 
conducted in order to provide updated local data regarding susceptibility profiles. 
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ABSTRACT  
Azole fungal resistance is becoming a major public health problem in medicine 
in recent years. However, it was known in agriculture since several decades. The 
extensive use of these compounds results in contamination of air, plants and soil. 
Indeed, the increasing frequency of life-threatening fungal infections and the 
increase of prophylactical use of azoles in high-risk patients, taken together both with 
the evolutionary biology evidence that drug selection pressure is an important factor for 
the emergence and spread of drug resistance can result in a dramatic scenario.  
This study reviews the azole use in agricultural and in medical context and 
discusses the hypothetical link between its extensive use and the progressive increase of 
azole resistance among human fungal pathogens.  
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INTRODUCTION 
The use of plant protection products (PPP) may have considerable negative 
effects on the environment [90]. The use of azole fungicides in agriculture started 
around mid-1960s; since then, such compounds have been used extensively during the 
last 30 years [181].  In the European Union half of the total land of cereals and 
grapevine is treated with azole fungicides. Notably, much smaller quantities of azoles 
are used in the United States for plant protection [182]. 
The azoles used in agriculture are generally sprayed every year over the cultured 
area in order to control mildews, rust and other diseases in cereals, ornamental plants, 
vegetables, fruits and vineyards. According to Matthews, the widespread use of these 
compounds results in contamination of air, plants and soil with a lot of small particles of 
fungicide [183]. 
The hypothetical risk that the massive use of azoles in agriculture could induce 
antifungal resistance among human pathogens started to be discussed several years ago. 
Agricultural azoles could stress fungal species either members of the endogenous 
saprophytic flora or exogenous to the human body. The imbalance of the endogenous 
fungal flora ecology could thus upset the population of medically important fungi.  
Human pathogenic fungi may therefore persist and thrive [87], and in this situation, 
health risks for human beings increase. 
In order to address this problem, in particular regarding the Portuguese situation 
relatively to azole use in agriculture, this review was organized according the following 
topics: 1. Use of azole fungicides in agriculture; 2. Azole fungicides in Portugal; 3. 
Mode of action of the azoles; 4. Hypothetical link between azole use in agriculture and 
human health; 5. Portuguese National Strategie plan for a sustainable use of plant 
protection products. 
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Use of azole fungicides in agriculture The growing request for food in quantity/quality 
has placed a drastic pressure on the productive sector, often at the expense of the natural 
elements, with progressive reduction or elimination of pristine landscape. The use of 
PPP in this context may have strong negative effects on the environment, especially 
with regard to the possible contamination of surface water and groundwater. Azole 
compounds are PPP which are also used for preservation of materials, such as paints, 
coatings, wall paper pastes, and are routinely applied to mattresses in order to prevent 
fungal growth. The most commonly compounds use in the European Union are 
imidazoles (Figure 1A - [184]), triazoles (Figure 1B - [185]), fluconazole (Figure 1C - 
[186]) and tebuconazole (Figure 1D - [187]).  
 
Figure1. Chemical structure of (A) imidazole, (B) 1,2,4 triazole, (C) fluconazole, and 
(D) tebuconazole. 
 
Genesis of azole antifungal resistance from agriculture to clinical settings 
 
80 
 
They are widely used in preharvest phase, in grain-growing and grass-growing 
environments, as well as at postharvest phase to prevent fungal spoilage [167] by yeasts 
like Candida spp., Cryptococcus spp, Rhodotorula spp., Trichosporon penicillatum, and 
Saccharomyces cerevisiae or filamentous fungi/moulds like Alternaria spp., Aspergillus 
spp., Fusarium spp., Geotrichum spp [95, 96]. In addition, they are also applied to treat 
plant infection when it becomes apparent. 
According to the manufacturer’s instructions, doses of 100g/ha should be used, 
corresponding approximately to 10 mg of azoles applied to 1 m2 of plant surface [87]. 
Data from the literature reveals that annually nearly 50% of the total acreage under 
cereal and grapevine production in Europe is treated with azole fungicides [188]. 
Comparatively, in the United States, less than 5% of the total crop area is treated with 
these compounds. In the European Union, the situation of the Netherlands must be 
stressed in particular, since the utilization of azole fungicides has almost doubled since 
the mid-1990s [113]. Several reasons are usually forwarded to justify the use of azoles 
in agriculture, in particular, the fact that these compounds are not expensive and that 
they exhibit broad spectrum activity. However, since azoles are very stable molecules, 
they can persist active in the soil and water during several months [91] and several fruits 
and vegetables [99, 100, 189].  Although the azole residues detected in many samples 
do not reach health hazards toxic levels, the amount could vary considerably. Data from 
the literature shows that considerable quantities of azole residues could persist in some 
food products during long time [87]. 
Farmers have been strongly encouraged to follow guidelines aiming to reduce the 
probability of developing resistance to agricultural antifungals and/or to minimise its 
extent and/or to increase the chance that any developed resistance would still be 
reversible. Such practices include the rotating use of antifungal products with different 
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modes of action, as well as the preferential practice of a limited number of interventions 
using higher dosages as opposed to more frequent applications with lower dosages. This 
does not, however, imply that the use of antifungal substances in agriculture should not 
be closely monitored, considering the risk of accumulation of azoles in the soils (the 
half-life time of azoles is usually longer than 1 year), and because the newer compounds 
may be also at the origin of resistance development. 
 
Azole fungicides in Portugal In the particular case of Portugal, there is a need to 
promote agriculture and invest in training farmers. According to the results of the 
Agricultural Census report [190], the social characterization of the Portuguese family 
farm population consists of 793 000 individuals representing, 7% of the resident 
population. The rural population has aged considerably between 1999 and 2009; the 
average age increased from 46 to 52 years old. The educational level is rather low; 40 % 
of subjects only attended the 1st cycle and 22% have no schooling. However, despite 
these social indicators, significant improvements were registered during the ten year 
period under study; illiteracy rate decreased by 7% and the frequency of senior 
secondary cycle and higher education increased by 3%. The typical profile of the 
Portuguese farmer nowadays is a 63 year old male, having just completed the 1st cycle 
of basic education, only having practical agricultural training and working in 
agricultural activities about 22 hours per week.  
By December 31, 2012, 907 PPP, based on 248 active substances were available in 
Portugal [191]. The largest volume of these substances available at the national market 
belong to the fungicides group, followed by herbicides and insecticides, representing the 
remaining products about 15% of the total PPP marketed. According to the Agricultural 
Statistics report the ratio between sales of PPP/agricultural area used was in 2008, 2009, 
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2010 of 4.6, 3.8 and 3.8, respectively. In case the total sales volume is subtracted with 
the value of sulfur and derivates, this ratio corresponds to values of 1.9, 2.0, and 1.9, 
respectively [191]. 
Sales figures of PPP at national level constitute an indicator that can provide an 
estimation about the use of such products in Portugal. The amount of PPP sold in 
Portugal during 2012 corresponded to a total of 12 462237 kg, expressed as active 
substances. The fungicides contributed with about 68.3% of the total of active 
substances sold, whereas sulphur represented 49.8 % of the total sales and 71.4% of all 
the fungicides sold.  Figure 2 represents an overview of fungicides sales by chemical 
group in Portugal between 2002 and 2012. Overall, a decrease in fungicides sales was 
registered from 2008 until 2012 [192]. In respect to azoles, a consecutive decrease in 
sales was registered between 2002 and 2005; however, after 2006 the values started to 
increase again, reaching a peak in 2012 (Figure 3) [192]. 
 
Figure 2. Sales of fungicides in Portugal between 2002 and 2012 [192]. 
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Figure 3. Sales of agricultural azole in Portugal between 2002 and 2012 [192]. 
 
Mode of action of the azoles Concerning the mode of action, all the azoles compounds 
interact and target the same active site in fungal enzyme, so agricultural azole 
fungicides share the mode of action with medical azoles [125]. This results in a 
fungistatic rather than fungicidal effect; in this sense the terminology often used in 
agriculture “fungicides” is ambiguous. This class of compounds are sterol 
demethylation-inhibitors and impair the synthesis of ergosterol [87, 125]. Sterol 
biosynthesis inhibitors (SBIs) are major compounds used as medical and agriculture 
agents for the control of fungal diseases. In many fungi the preponderant sterol is 
ergosterol. Azoles compounds interfere with the activity of fungal lanosterol 14 alpha-
demethylase, an enzyme responsible for the transformation of lanosterol in ergosterol. 
Ergosterol is an important compound of the fungal cytoplasmatic membrane; the 
impairment of its metabolism induces cell membrane disorganization and decrease of 
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fungal growth. Moreover, fungal growth arrest can also result from the accumulation of 
toxic ergosterol precursors [193].  
The available SBIs-fungicides can be classified into four classes according to 
their respective target sites, which are membrane bound enzymes, namely: 
thiocarbamates or allylamines (squalene epoxidase), inhibithors of C14-demethylation 
or DMIs, Amines (∆14 reduction or ∆8-> ∆7 – isomerization) and hydroxyanilides (C4-
demethylation). However, several resistance mechanisms to SBIs have been described. 
The two major involve either alterations of the target enzyme, which result in a reduced 
affinity to fungicides or a decrease of the intracellular drug accumulation, that is linked 
to an over expression of membrane transporter proteins.  
 
Hypothetical link between azole use in agriculture and human health Many authors 
equate antifungal resistance only in terms of clinical settings. Indeed, agriculture has 
been blamed for it, in particular due to the use of concentrated pest control compounds 
that outflow fungicides into nearby watercourses. Several reports claim that antibiotic 
resistance is also a natural occurrence in the soil. In fact, microorganisms inhabiting soil 
have to strive for energy sources; it is known that, some bacteria and fungi developed 
the ability to produce antibiotic compounds in order to destroy their competitors. Such 
microorganisms are thus naturally immune to the effects of their own excretions [194]. 
The development of resistance to azoles in plant fungal pathogens is complex 
and generally progressing in small steps.  First descriptions date from long time ago and 
claim that some plant pathogens acquired azole resistance following agricultural 
exposure [195]. Data from the literature describes resistance or tolerance to triazole 
fungicides for important crop pathogens such as wheat, barley and strawberry [116]. 
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Although in Portugal resistance to triazoles in vineyard powdery mildew has been 
detected in the past [196], still recent studies described this situation [117]. 
Over the last two decades, clinically important fungal infections have become 
more prevalent because medical progress allows the survival of an increasing number of 
immunocompromised patients. However, resistance to antifungal drugs also became a 
critical medical problem. Antifungals of a classes similar to those used in clinical 
practice are widely used in agriculture where resistance to antifungals also became a 
problem. Improvement the methods of application and treatment control have been 
devised in order to limit the consequences of this emerging resistance, allowing the 
continued use of such drugs. 
However, it has been proposed, that there may be a direct relation between the 
development of resistance to azole fungicides used in agricultural practice and the 
development of resistance to azole antifungals observed in clinical settings [7]. 
Exposure of a microorganism to any antibiotic involves a risk of resistance developing 
through the process of selection. The knowledge about the rate and extent of the 
emergence of resistant organisms [197] and whether this resistance is reversible or not, 
is a very relevant issue to clinical medicine. Resistance depends upon a variety of 
factors and conditions, including the mechanisms of action of the compound, the target 
site(s) in the organism and their number, the risk of resistance transference between 
individual organisms and species, and the mechanism of such resistance. 
  Resistance in fungi and the mechanisms involved in its development and 
transmission differ in some extent from those seen in bacteria. There is no evidence that 
the genes that confer resistance to fungi can be transferred horizontally, a key difference 
with bacteria. There are two forms of resistance, primary (or intrinsic) and secondary. In 
primary resistance, the fungal organism cannot be inhibited even by high concentrations 
Genesis of azole antifungal resistance from agriculture to clinical settings 
 
86 
 
of an antifungal drug. For example, Aspergillus fumigatus is intrinsically resistant to 
fluconazole and does not respond at all to this drug. Similarly, Candida krusei and C. 
glabrata isolates are often intrinsically resistant to fluconazole. Conversely, fluconazole 
resistance in Candida albicans can emerge de novo during prolonged treatment; which 
is an example of secondary resistance [198].  
There are at least three different mechanisms by which antifungal drug 
resistance might arise. They can involve increased efflux of drug, altered target 
demethylase sites and the availability of alternative pathways for the synthesis of cell 
membrane sterols. Candida krusei shows intrinsic resistance to fluconazole largely due 
to the last mentioned mechanism. There is also evidence that in clinical settings the 
adoption of some therapeutic strategies to treat patients over long periods or to prevent 
infections through antifungal prophylaxis can result in selection of resistant organisms, 
either of the same or of different species. Several studies have shown that a strong and 
persistent antimicrobial pressure upon a microbial population will undoubtedly lead to 
the selection of resistant clones, particularly whenever the antimicrobial agent induces a 
static effect instead of a biocidal effect [194]. This situation can happen in fungi 
submitted to azole action. Since azoles represent first line clinical antifungals, the topic 
of azole resistance is of great medical relevance. Azole resistance can thus 
hypothetically result from exposure of the fungi to azole compounds, which can happen 
in vivo (in azole treated patients) or due to the use of these compounds in the 
environment, namely agriculture use [158]. The discussion about the risk that the 
massive use of azoles in agriculture could induce cross-resistance among human fungal 
pathogens has been debated along the recent years. The massive use of azoles in 
agriculture would stress susceptible species of the fungal flora, both in nature but also at 
human endogenous niches. This disturbance in the fungal flora ecology could result in 
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considerable changes among the population of medically important fungi; human 
pathogenic fungi may thus persist and increase [87]. Specifically, species that could 
develop azole resistance would profit from such an environmental repeated and 
selective pressure. In this situation, health risks for human beings might increase 
seriously.  In addition, new resistance mutations could also developed in the 
environment. Studies addressing the epidemiology of invasive fungal infections are of 
high relevance in order to determine the hypothetical impact of such anthropogenic 
activities upon the susceptibility profile of yeast and filamentous fungi and also to 
report any emergent species. In Portugal, two studies conducted at the same institution, 
within a ten year interval, revealed several relevant differences not only in susceptibility 
patterns but, most importantly, regarding species distribution [67, 144]. 
In 2009, Snelders and co-workers provided for the first time evidence that 
patients with invasive aspergillosis due to azole resistant A. fumigatus might have 
acquired the organism from the environment [158]. Invasive aspergillosis is a very 
dangerous opportunistic fungal infection. The conidia of Aspergillus spp. become 
airborne from soil or decaying organic matter and patients become infected usually by 
inhalation from such a reservoir [113]. According to this study, resistant strains of A. 
fumigatus to medical azoles were found in the soil and compost from areas nearby to the 
admission hospital [158]. The dominance of a single resistance mechanism and the 
genetic homology between clinical and environmental isolates suggested that the 
acquisition of azole-resistant isolates from the environment was the most important 
infection route.   
Azole resistance among A. fumigatus isolates was not only found in Dutch 
hospitals [67]; resistant isolates were also detected in several European countries such 
as in Spain [199], Belgium [200], Denmark [201], Sweden [202], France [203].  
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Human and animal fungal pathogens such as Coccidioides, Histoplasma, 
Aspergillus and Cryptococcus do also thrive in the environment, including plants and 
food products. It should also be stressed that only sporadic yeast species are endogenous 
to the flora of healthy human beings. Thus, in most occasions, the fungal pathogens are 
taken up from the environment. Thus, environmental resistant isolates could have 
developed antifungal resistance following a prolonged selective azole pressure. 
Therefore, the probability that an individual might be exposed to an environmental 
resistant fungal organisms is real and high. Nevertheless, the effect of residual azoles 
present in vegetables and other food products upon the endogenous native fungal flora 
of humans should not be neglected and may also contribute to the emergence of 
antifungal resistance at endogenous niches. 
In the case of A. fumigatus, it was concluded that two distinct models of 
resistance might have developed. One of them occurs following long time-exposure to 
azole treatment, as might occur in clinical settings which is supported by several 
possible genetic mutations. The other model is facilitated by a single mechanism, 
TR/L98H mutation, that occurs in environmental isolates under the selective pressure of 
azole fungicides used in agriculture. This kind of mutation started spreading worldwide 
and has nowadays also been described outside Europe [204]. A very recent study 
conducted in France describes a clinical case of a French farmer who developed 
invasive aspergillosis caused by an azole-resistant A. fumigatus with the TR34/L98H 
mutation following a hematopoietic stem cell transplantation [205]. This farmer had 
worked in fungicide-sprayed fields from where A. fumigatus TR34/L98H isolates were 
collected. This study supports the assumption that immunosuppressed patients might be 
infected with environmental azole resistant strains. 
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 The adoption of measures in order to control this problem should be undertaken, 
in particular in the Netherlands, where the TR/L98H mutation is endemic [87]. 
Interestingly, in Portugal, back in 2007 Araújo et al. [132] compared the antifungal 
susceptibility profile of different Aspergillus species recovered from environmental and 
clinical sources and found high MIC levels of clinical antifungals among environmental 
strains. 
Verweij and co-workers reported cross-resistance between azoles, which constitutes a 
very relevant clinical issue, with relatively few therapeutic options available in the case 
of invasive Aspergillus infections [206]. More recently, several studies demonstrated 
cross resistance between agricultural and medical azoles [113, 125]. Faria-Ramos and 
co-workers, clearly demonstrated that exposure of clinically relevant moulds and yeast 
organisms to azoles used in agriculture does result in the emergence of cross-resistance 
to clinical azoles, which may not be reversible [118, 119]. 
Additional research efforts aiming to reduce the emergence of fungicide resistance are 
urgently needed, both in agriculture and in medical settings. Since the mechanisms 
providing the basis for fungicide resistance are likely to be conserved between plant and 
human pathogens, plant pathologists and medical microbiologists should develop 
effective strategies counteracting the development of antifungal resistance, in a 
concerted action. 
 
Portuguese National Strategie Plan for a sustainable use of plant protection 
products The Directive No. 2009/128/EC is an innovation in the context of the 
Community legislation about PPP. For the first time legislates about the use of PPP in 
order to protect human health and environment from the possible risks inherent to its 
use. 
Genesis of azole antifungal resistance from agriculture to clinical settings 
 
90 
 
In order to operationalize the implementation of this Directive at national level, 
the law nº. 26/2013 was published. This regulates the distribution, sales and application 
of PPP by professional users as well as adjuvants for PPP; it also sets the monitoring 
procedures for the use of PPP. Together with the Law nº. 86/2010 constitutes (which 
establishes a mandatory inspection scheme of PPP and its application using equipment 
authorized for professional use) the transposition into national legal order of that 
Community law. 
The article 51º of this law, envisaged the creation of National Action Plans.  
These plans aimed at reducing the risks and effects of the use of PPP on human health 
and upon the environment, also promote the development of integrated protection 
technical alternatives to reduce dependence of the use of conventional PPP. 
The Portuguese National Plan has been prepared with the collaboration of 
various agents, either from public or private sector, without which would not have been 
possible to achieve the intended goals. It must also be pointed out that the 
implementation of this plan will only be effective with the committed collaboration of 
all the agents involved in manufacture, storage, sale and use of PPP, as well as those 
responsible for managing the effects and risks associated with the use of PPP. The 
correct application of PPP can be encouraged by the training of professionals, 
appropriate counselling at the point of sale, and monitoring/supervision of compliance 
by professional users. In the act of sale, adequate information about the use of PPP and 
the risks and safety instructions regarding human health, should be provided to buyers, 
in order to enable the adequate management of the risks inherent to the products 
concerned. 
The protection of professionals configures primarily a matter of safety and 
health regarding to the professional handling field use and application of pesticides. 
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Risks may include not only acute intoxication, but also chronic and sub-chronic risks, 
resulting from prolonged exposure. The lines of action chosen for this intervention area 
are: i) Protection of professional users (commercial and storage settings); ii) Reduction 
of exposure; iii) Limitation of the use of certain PPP [207]. 
The main measure of protection for non-professional users is restricting its 
access to a limited category of PPP. In any case, such buyers should be provided 
awareness of the risks associated with PPP use and about promotion of good general 
practices regarding its use. On the other hand, it is intended that at points of sale buyers 
are properly advised, as recommended by the legislation. 
In order to assess the progress made in reducing the risks and adverse effects of 
the use of PPP, both to human health and the environment, monitoring plans should be 
in place so that, based on a sample of professional users and predefined criteria, it will 
be possible to assess the progresses made in the implementation of the general 
principles of integrated protection. 
In addition, is also very important to emphasize the importance of the 
contribution of scientific research and field application of the most recently available 
scientific and technological information in improving resources and instruments 
available to the professional users, including complementary or alternative means of use 
of PPP. 
Concluding, fungicide-based plant protection is at present indispensable for 
efficient and large-scale crop production. Notably, modern fungicides should exhibit 
negligible acute toxicity, and the regulations for fungicide application should ensure the 
availability of safe food. As long time periods and enormous financial investments are 
required to develop new fungicides, particular care must be taken in order to prevent the 
emergence of fungicide resistance. This is particularly important, since fungicides with 
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novel modes of action are rarely found, and resistance to single-target fungicides may 
occur within the first few years of its field use. 
The key to prevent or at least delay the onset of development of fungicide 
resistance in agriculture is the preparation of efficient fungicide mixtures as well as the 
rotation between fungicides with different modes of action during a crop campaign. The 
recommendations to maintain highly efficient fungicides in the market preclude the use 
of monofungicides, in order to keep the use of fungicides applied above a threshold 
allowing quantitative resistance to develop. The strategy developed during the last 
decades was to apply single-target fungicides, which resulted in a strong selective 
pressure for mutants with a modified fungicide-binding site. As fungicides with more 
than one target are not easy to be overcome by mutations, the focus in fungicide 
screening should also be directed towards identifying multi-site inhibitors. After having 
such fungicides available, the risk of rapid occurrence of qualitative resistance might be 
strongly and effectively reduced. Particular attention should be devoted to the 
assessment of development of cross-resistance to clinical antifungals while a strict 
monitoring of the emergence of fungal strains with resistance mechanisms, as well as 
variations in species distribution regarding both plant and human pathogens should be 
implemented. 
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Overall discussion 
 
 Over the past three decades, the world has witnessed the rise of fungi as a major 
cause of human disease, especially among debilitated and immunocompromised 
patients, whose number continues to increase [5]. Despite its growing importance, many 
fungal infections have been neglected over the years. However, there are two well-
known responsible fungal pathogens: Aspergillus fumigatus and yeasts belonging to the 
Candida genus. More recently, the emergence of antifungal resistance among such 
pathogens along with a somewhat narrow antifungal armamentarium have stressed the 
relevance of the topic. Charles Darwin´s evolutionary concept of “natural selection” 
tells us that it was inevitable for this to happen in result either from antifungal 
prophylactic (perhaps abusive) use or also from prolonged regimen therapies that are 
also very common in clinical practice; sooner or later resistance would emerge [208]. 
The question is: where natural resistant strains came from? Where did the antifungal 
resistance of isolates that where never before in contact with clinical antifungals came 
from? Can this resistance develop by cross-resistance with agricultural antifungals? 
This question has been raised a little all over the world by now. We tried to address it 
with two original studies using Candida and Aspergillus, as described in chapters 3 and 
4, respectively.  
The prevalence of IFIs is changing greatly across different geographic areas and 
it is also dependent of many factors, starting on the host condition itself, passing 
through the antifungal therapy modalities used and, finally, to the pathogen virulence 
attributes [70, 84, 85]. In order to understand our national reality a multicentric survey 
on yeast species distribution and its in vitro susceptibility profile to clinical antifungals 
was carried out, as described in chapter 2. From this study we could obtain important 
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information not only about clinical and demographic data but also about cryptic species 
such as C. parapsilosis and C. glabrata complex, along with the resistance rate to the 
most frequently used clinical antifungals. From the 240 fungemia episodes reported in 
this study we have calculated an incidence of 2.4 per 1.000 admissions, decreasing to 
2.1/1.000 when defined as nosocomial fungemia, corresponding to 86% of all the 
fungemia episodes. In fact, in most surveillance studies, healthcare-associated fungemia 
in hospitalized patients remains the main source of infection, frequently representing 
more than 80% of the cases [43, 145]. C. albicans remained the leading agent of 
fungemia; however, in agreement with findings in Europe the proportion of non-C. 
albicans is rising [133]. Our data confirmed other Spanish and Brazilian studies where 
the second position was occupied by C. parapsilosis, being C. glabrata the third [142, 
148]. The latter was also the deadliest species with more than a half of the patients 
dying within 30 days after fungemia detection which represents the highest death 
burden in Europe [37, 43, 141, 145]. We did not find any isolate of the sibling species 
of C. glabrata, C. nicavariensis or C. bracarensis; only C. glabrata sensu stricto was 
found in this study. The same occurred in similar studies from Mediterranean countries 
and also in reports from Brazil [142, 148-150]. Interestingly, from 55 C. parapsilosis, 
49 were sensu stricto while 4 were C. orthopsilosis and 2 C. metapsilosis. Most yeasts 
were isolated from patients admitted in intensive care units and surgical wards, being 
57% males and 32% aged between 41-60 years old. The overall mortality rate was 25% 
and it was associated with more than thirty days of hospitalization and patients with one 
of the following condition: 1) female gender; 2) more than sixty years old; 3) under 
dialysis and 4) infected by C. glabrata. The susceptibility testing results were 
interpreted by two distinct protocols, CLSI and EUCAST, and the overall susceptibility 
rates ranged from 74 to 97% for echinocandins and from 84% to 98% for azoles. It is 
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noteworthy that resistance rates discrepancies between protocols were found with C. 
albicans and C. glabrata for echinocandins and with C. parapsilosis and C. tropicalis 
for azoles. Besides the obvious importance of establishing an accurate and actual 
portuguese scenario detailing species distribution and susceptibility profiles, this study 
enabled us to obtain a considerable number of yeast isolates from several species and 
with different susceptibilities to the most commonly used clinical antifungals. From this 
newly assembled collection, our next step was also to determine its corresponding MIC 
values to the most frequently used fungicides in crop fields. Such results helped us to 
selected one isolate each of C. albicans, C. parapsilosis and C. glabrata that were 
susceptible to clinical and agricultural antifungals. Fulfilled this premise, we carried on 
with in vitro induction assays with one of the most frequently fungicide used in 
Portugal, PCZ – a study detailed in chapter 3. During the 90 days of induction, the MIC 
values were determined every 10 days and, at the end, we found that cross-resistance 
did develop. In fact, the three species under investigation revealed a corresponding 
progressive increase of MIC value of PCZ comparatively with the respective parental 
strain. A concomitant increase was achieved for each clinical azole tested – FLC, VCZ 
and POS – but only for C. glabrata; in fact, cross-resistance emerged following the 
selective pressure of a fungicide. No cross-resistance was observed regarding 
echinocandin for any of the tested species. We were expecting such a result since 
echinocandins belong to a class of antifungals that act very distinctly from azoles or 
DMIs fungicides. Interestingly, the obtained resistance and cross-resistance was stable, 
i.e., the MIC values did not revert to the initial value in the absence of the inducer 
fungicide, in any of the tested species. Since this cross-resistance phenomena only 
happened with C. glabrata we considered that a specific genetic event should be 
responsible for such cross-resistance, not only because it was a permanent susceptible-
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to-resistant phenotype alteration but also because C. glabrata is a haploid cell and for 
that reason cells might be more prone to genetic modifications. We screened the most 
common azole resistance associated genes, namely: CDR1, PDH1, YOR1, SNQ2, PDR1 
and ERG11. In contrast to several other studies reporting genetic alterations responsible 
for azole resistance, to the best of our knowledge, this was the first time that genes like 
YOR1 and PDH1 have such an upregulation, 66.8 and 45.5 fold overexpressed, 
respectively. All the other genes were also upregulated but to a smaller extent while no 
ERG11 contribution was verified. Can this particular genetic context of resistance only 
arise from a fungicide azole selective pressure? It would certainly needs additional 
studies to address whether the involvement of these genes is specifically triggered after 
a fungicide induction of cross-resistance. Besides a few speculative reports published 
years ago [42, 116, 167], the only work done with yeasts that can allow to clearly trace a 
correlation between agricultural use of fungicides and azole clinical resistance was latter 
herein discussed.  
In contrast, the evidence that A. fumigatus species are extremely stressed by the 
use of agricultural fungicides is now fully documented around the globe. In fact, there is 
a strong indication that A. fumigatus clinical azole resistance arose from the 
environment, namely from fungicides use in crop fields. So, we decided to recreate the 
same methodologic approach described in chapter 3 but this time with A. fumigatus 
species – as detailed in chapter 4. Following the induction assays we found that besides 
the emergence of cross-resistance, PCZ exposure also caused marked morphological 
colony changes, both macro and microscopically. The macroscopic colony changed in 
pigmentation from the original greenish color to a totally white mycelia, corresponding 
to hyphae with immature little conidiophore structures without conidia. Although these 
pigmentation changes had already been described as a consequence of azole exposure, 
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yet no clear explanation is given of such phenomena besides one report by Varansi and 
colleagues suggesting that it possible may be due to the fact that azoles bind to a 
phytochrome-like regulatory molecule, inhibiting the initiation and development of 
conidiophores in Aspergillus species [176]. The high MIC values achieved for PCZ 
maintained stable. On the other hand, in the absence of PCZ, we observed different 
repercussions either within the isolates tested and also regarding the cross-resistance 
achieved for the three clinical azoles. For all the isolates tested, the MIC value of VRC 
and POS changed but not enough to revert to a susceptible phenotype, while for ITZ we 
observed a complete reversion to the initial MIC value, i.e., LMF11 and LMN60 
became susceptible again and although LMF05 reverted to the original MIC value, 
2mg/ml, this was already falling into the resistant category since the beginning of the 
induction assay. The morphological typical aspect of all isolates reappeared after PCZ 
removal.  
It should be stressed that cross-resistance developed soon after 30 days of 
exposure to an agricultural antifungal. Certainly, we cannot deny the fact that an in vitro 
assay lacks the influence of innumerous factors happening either in vivo or in the field; 
the poor relationship between in vitro and in vivo is known in science [48]. Yet, the 
clear suggestion of our studies was that, indeed, the use of fungicides in nature may 
cause serious problems in the medical field – the potential of saprophyte fungi to suffer 
the selective pressure of fungicides with very similar mode of action to those 
antifungals used to treat humans and develop cross-resistance and then compromise 
clinical efficacy of medical drugs.  
Finally, in chapter 5, we discussed about the origin/emergence of azole 
antifungal resistance and its hypothetical link to fungicide use in agriculture, addressing 
in particular the Portuguese situation. We report the national strategy plan for the use of 
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Plant Protection Products (PPP) upon several directives and law implemented since 
2009. It regulates the distribution, sales and application of PPP. The Portuguese plan 
aims to reduce the risks and effects of the use of PPP on human health and the 
environment but most importantly to promote the development of alternatives to reduce 
the dependence of the use of conventional PPP. In Portugal the largest volume of these 
substance available at the national market belongs to the fungicides group, followed by 
herbicides and insecticides. More than 12. 000 tons of PPP have been sold during 2012; 
fungicides represent about 68% and, from these, more than 5 000 000 kg were azoles 
[191]. Indeed, several reasons are given to justify the use of azoles in agriculture, in 
particular, the fact of being inexpensive and having a broad spectrum of activity. 
However, they can persist active in soils and water for several months [91] as well as in 
fruits and vegetables [99, 100, 189]. Therefore, farmers are being instructed to follow 
the most recent guidelines in order to minimize the collateral damage of such use. All 
the working plans upon agriculture activities must be monitored on site in order to 
prevent or at least delay the onset of azole fungicide resistance. The most important 
factor to prevent it must be the preparation of efficient fungicide mixtures, i.e., to join 
fungicides with multiple modes of action and exclude the use of monofungicides [207]. 
It is known that the use of these single-target fungicides (monofungicides) results in a 
strong selective pressure for genetic events overcoming its target site. Also, it is of 
extremely importance to insure surveillance studies addressing the susceptibility profile 
of both environmental and clinical isolates either for yeast or for filamentous fungi. The 
last and perhaps the biggest challenge is to develop new antifungal drugs – part of the 
challenge is related to the difficulty in finding suitable mammalian-excluding 
biochemical targets in eukaryotic pathogens and to the pharmaceutical economic 
interests and priorities. Nonetheless, new antifungals are indeed urgently needed mainly 
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because, in the setting of azole resistance, treatment failure is closely associated with 
resistance and alternative therapeutic options are very scarce.  
Soon after the first article on this topic in 2007, many studies addressing the 
same question have been published and all suggest the existence of an environmental 
route of resistance driven by fungicides [64, 101, 113, 115, 117, 127, 167, 209-212]. 
The repercussions and impact of such cross-resistance in human health is also being 
discussed but still no major measures have been taken in agriculture. In fact, simply 
prohibiting use of the fungicides is not feasible, as this might result in the return of crop 
disease epidemics and consequent food shortages and incalculable economic losses. 
Two extreme scenarios can be hypothetically raised: 1) on the medical field what could 
happen if the efficacy of the current and limited antifungals is lost? What if clinicians 
have no antifungal available antifungal to treat patients with an invasive fungal infection 
by a resistant isolate? This is already a real concern among the medical/clinical 
scientific community [71, 115]; 2) With an estimated global population of more than 7.5 
billion people, agriculture cannot afford to exclude the use of fungicides. What would 
happen if cereals, vegetables and fruits crops production was tremendously reduced? 
Agricultural industry has to use fungicides to optimize food production; otherwise, how 
could so many people be fed? Also, several reports from agricultural scientific area 
debate such hypothetical scenario [213-216]. The most recent effort is called Integrated 
Pest Management (IPM) and tries to provide feasible alternatives to fungicide 
application, maintaining a high agricultural production pattern [217, 218]. 
The concern is real and translational within these two scientific communities,: clinical 
and agricultural [127, 209]. It must be stressed that ITC was introduced in early 1980s 
and the first isolation of a resistant A. fumigatus from a patient with invasive 
aspergillosis and receiving long-term azole therapy occurred in 1989 [106]. On the other 
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hand, azole fungicides were introduced in the 70s but just very recently (2007) resistant 
isolates were recovered from patients with invasive aspergillosis with no prior or actual 
azole therapy [67]. Therefore, it was suggested that selection for resistance could 
occurred in the environment since A. fumigatus, as a saprophyte, inhabit soils and 
decaying matter. The hypothesis of agricultural fungicides being the main responsible 
cause for antifungal cross-resistance, is still controversial. Firstly, from an ecological 
point of view, A. fumigatus is not commonly isolated from residue surface in cropping 
areas [219] but it can be found at farms sewage [220], compost [220] and flower fields 
[128]. Also, it is estimated that azole fungicides applied in crop fields have a half-time 
that varies from 20 to 200 days depending on soil type but more than two years are 
needed before soils are expected to be considered “azole free” [221]. However, azoles 
are moderately lipophilic so they are strongly adsorbed to soil organic matter and may 
become quickly unavailable to soil microflora [222]. Secondly, laboratories involving 
selection for resistance are scarce but on the other hand surveys analyzing genotypic 
changes in isolates from both clinical and environmental sources are considerable [54, 
114]. Interestingly, such surveys always suggest that evolutionary changes involving 
different resistance targets are far greater in the clinic than in nature, which probably 
reflects higher selective pressure in patients receiving azole therapy than what might 
occurs in field crops. Another feature that certainly biases this situation is the existence 
of sibling species of A. fumigatus, that are known to be less susceptible or even resistant 
to medical azoles and are difficult to identify in a routine hospital laboratories [16, 17, 
48]. Several authors have acknowledged that the studies herein described are the ones 
confirming the selection, convey by agricultural fungicides exposure, for resistance and 
promotion of cross-resistance to clinical antifungals [15, 127, 210, 223-230]. 
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As a conclusion of this thesis, altogether, it seems evident that both medical 
relevant yeasts and filamentous fungi can develop cross-resistance to medical 
antifungals following its exposure to agricultural fungicides. 
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